Mycobacterial immunotherapy for cancer treatment

JP2023552674A5Inactive Publication Date: 2024-11-13IMMODULON THERAPEUTICS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527652
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-03-29
Filing Date
2021-11-05
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 00000036_0000
    Figure 00000036_0000
  • Figure 00000036_0001
    Figure 00000036_0001
Patent Text Reader

Abstract

The present invention provides immunomodulatory agents for use in the adjuvant, neoadjuvant, or periadjuvant treatment, reduction, inhibition, or control of cancer in patients who have undergone or will undergo tumor resection and / or one or more additional anti-cancer treatments or agents, preferably checkpoint inhibitor therapy. The present invention also describes the use of one or more additional anti-cancer treatments or agents in the adjuvant, neoadjuvant, or periadjuvant setting, as well as protocols and dosing regimens for use.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to the field of cancer therapy. In particular, the present invention relates to methods of preventing, treating, or inhibiting the development of tumors and / or metastases in a subject through adjuvant therapy, including neoadjuvant, adjuvant, and peri-adjuvant regimens and treatments. [Background technology]

[0002] In people with cancer, treatment regimens often include tumor surgery, chemotherapy, radiation therapy, or forms of immunotherapy. In progressive cancers, antitumor immunity is often ineffective due to the tightly regulated interplay of pro- and anti-inflammatory, immunostimulatory, and immunosuppressive signals. It is now believed that the immune system is constantly monitoring and eliminating newly transformed cells. Thus, cancer cells can change their phenotype in response to immune pressure to evade attack (immunoediting) and upregulate the expression of inhibitory signals. Through immunoediting and other destructive processes, primary tumors and metastases maintain their survival.

[0003] PD-1 and other corepressor receptors, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), B- and T-lymphocyte attenuator (BTLA; CD272), T-cell immunoglobulin and mucin domain-3 (TIM-3), and lymphocyte-activation gene-3 (LAG-3; CD223), are often referred to as checkpoint regulators. These checkpoint regulators act as molecular "tollbooths," allowing extracellular signals to dictate whether cell cycle progression or other intracellular signaling processes should proceed.

[0004] In addition to specific antigen recognition through the T cell receptor (TCR), T cell activation is regulated through a balance of positive and negative signals provided by costimulatory receptors. These surface proteins are typically members of the TNF receptor superfamily or the B7 superfamily. Agonistic antibodies against activating costimulatory molecules and blocking antibodies against negative costimulatory molecules can enhance T cell stimulation and promote tumor destruction.

[0005] Two specific ligands for PD-1 have been identified: programmed death-ligand 1 (PD-L1, also known as B7-H1 or CD274) and PD-L2 (also known as B7-DC or CD273). PD-L1 and PD-L2 have been shown to downregulate T cell activation after binding to PD-1 in both mouse and human systems (Okazaki et al., Int Immunol., 2007; 19: 813-824). The interaction of PD-1 with its ligands, PD-L1 and PD-L2 expressed on antigen-presenting cells (APCs) and dendritic cells (DCs), transmits negative regulatory stimuli, thereby downregulating activated T cell immune responses. Blockade of PD-1 suppresses this negative signal and amplifies T cell responses.

[0006] The PD-L1 / PD-1 signaling pathway is a major mechanism of cancer immune evasion for several reasons. First, and most importantly, this pathway is involved in negatively regulating the immune response of activated peripheral effector T cells. Second, PD-L1 is upregulated in the tumor microenvironment, and PD-1 is also upregulated on activated tumor-infiltrating T cells, potentially reinforcing a vicious cycle of inhibition. Third, this pathway is intricately involved in both innate and adaptive immune regulation through bidirectional signaling. These factors make the PD-1 / PD-L1 complex a focal point through which cancer can manipulate the immune response and promote its own progression.

[0007] The first immune checkpoint inhibitor to be tested in clinical trials was the CTLA-4 monoclonal antibody ipilimumab (Yervoy, Bristol-Myers Squibb). Anti-CTLA-4 monoclonal antibodies are potent checkpoint inhibitors that remove the "brakes" from both naive and antigen-experienced cells. The treatment enhances the antitumor function of CD8+ T cells, increases the ratio of CD8+ T cells to Foxp3+ regulatory T cells, and inhibits the suppressive function of regulatory T cells. The major drawback of anti-CTLA-4 monoclonal antibody therapy is the potential for autoimmune toxicity.

[0008] TIM-3 has been identified as another important inhibitory receptor expressed by exhausted CD8+ T cells, and in mouse cancer models, it has been shown that most dysfunctional tumor-infiltrating CD8+ T cells indeed co-express PD-1 and TIM-3.

[0009] LAG-3 is another recently identified inhibitory receptor that functions to limit effector T cell function and enhance the suppressive activity of regulatory T cells. It has recently been shown that PD-1 and LAG-3 are extensively coexpressed by tumor-infiltrating T cells in mice, and that combined blockade of PD-1 and LAG-3 elicits potent and synergistic antitumor immune responses in mouse cancer models.

[0010] Immune checkpoint inhibitor therapy has been particularly successful in melanoma, and currently approved treatments for melanoma include anti-PD-1 regimens (nivolumab and pembrolizumab), anti-CTLA-4 regimens (ipilimumab), and combined anti-PD-1 / CTLA-4 regimens (nivolumab-ipilimumab). Long-term survival data for melanoma patients treated with ipilimumab (anti-CTLA-4) indicate that 20% of patients demonstrate evidence of ongoing durable disease control or response 5 to 10 years after initiation of treatment. The response rate for melanoma patients treated with pembrolizumab (anti-PD-1) was 33% at 3 years, and 70 to 80% of initial responders maintained their clinical response.

[0011] However, despite ongoing advances in cancer management through surgical procedures as well as immunotherapy, many patients still face extremely poor prognoses. For example, mismatch repair-deficient (dMMR) cancers with microsatellite instability (MSI) remain problematic and are particularly prevalent in elderly patients due to a high rate of methylated hMLH1 gene promoters. Given that the median age of newly diagnosed colorectal cancer patients is over 70 years, such dMMR cancers are unique to this disease. In the German ColoPredict registry, the proportion of dMMR tumors is up to 25% in stage II colorectal cancer and 20% in stage III colorectal cancer. The standard treatment for stage III colorectal cancer is currently oxaliplatin- and fluoropyrimidine-based adjuvant chemotherapy. However, for many patients, including those over 75 years of age, oxaliplatin is not recommended by some guidelines and is often not feasible due to underlying comorbidities in older patients (Nitsche et al. 2017, Gastrointest Tumors 4(1-2): 11-19). Patients with stage III colorectal cancer who are not treated with adjuvant oxaliplatin-based chemotherapy have a relatively high recurrence rate, with 3-year disease-free survival and 5-year overall survival rates of only 60% and 67%, respectively (Gill et al. 2014, Indian J Med Paediatr Oncol. 35(3): 197-202).

[0012] Therefore, there is a need for alternative treatment options that improve the unfavourable prognosis of patients with stage III dMMR colorectal cancer who are ineligible for adjuvant oxaliplatin-based chemotherapy, and indeed also improve the prognosis of patients with other difficult-to-treat and / or highly recurrent cancers.

[0013] It is therefore an object of the present invention to provide a therapy for treating cancer in patients undergoing tumor resection or checkpoint inhibitor therapy, which therapy comprises a non-viable mycobacterium used as a neoadjuvant, periadjuvant, or adjuvant agent or therapy to maximize the effectiveness of the surgery or checkpoint inhibitor therapy. Summary of the Invention

[0014] The present invention provides an effective method of treating, reducing, inhibiting, controlling, and / or preventing the establishment of cancer and / or metastasis in patients who have undergone or will undergo tumor resection surgery or administration of one or more additional anti-cancer treatments or agents, preferably checkpoint inhibitor therapy, by administering an immunomodulatory agent comprising a non-pathogenic, non-viable mycobacterium after and / or before said surgery or checkpoint immunotherapy.

[0015] Thus, in a first aspect of the present invention there is provided an immunomodulatory agent comprising a non-pathogenic, non-viable mycobacterium for use in the adjuvant, neoadjuvant or periadjuvant treatment, reduction, inhibition or control of cancer, including a primary tumour, in a patient who has undergone or will undergo tumour resection and the administration / administration of one or more additional anti-cancer therapies or agents, preferably checkpoint inhibitor therapy, and optionally wherein the patient does not present with metastases to any organ remote from the primary tumour.

[0016] In a second aspect of the present invention, there is provided a method for treating or controlling cancer, including primary tumors, in a patient who has undergone or will undergo tumor resection, comprising administering to the subject simultaneously, separately or sequentially: (i) a non-pathogenic, non-viable mycobacterium; (ii) tumor resection; and (iii) one or more additional anti-cancer treatments or anti-cancer agents, which results in enhanced therapeutic efficacy compared to administration of the non-pathogenic, non-viable mycobacterium alone, administration of the one or more additional anti-cancer treatments or anti-cancer agents alone, or tumor resection alone.

[0017] The invention will now be described with reference to the following drawings. [Brief explanation of the drawings]

[0018] [Figure 1] Figure 1 shows a schematic diagram of a clinical trial investigating the adjuvant (post-operative) use of a combination of the invention, specifically Mycobacterium obuense (M. obuense) and the checkpoint inhibitor (anti-PD-L1) atezolizumab, in the treatment of stage III, R0 resected, MSI-high / dMMR patients who are ineligible for or have refused oxaliplatin and who have an ECOG performance status of 0, 1, or 2 (see Example 3). [Figure 2] Figure 2 shows a schematic / flowchart of a clinical trial investigating the combination of the invention, specifically Mycobacterium obuense and the checkpoint inhibitor (anti-PD-L1) atezolizumab, in neoadjuvant (pre-operative), adjuvant (post-operative), and combined periadjuvant regimens, in the treatment of stage III, resectable, MSI-rich / dMMR patients who are ineligible for or have refused oxaliplatin and who have an ECOG performance status of 0, 1, or 2 (see Example 4). DETAILED DESCRIPTION OF THE INVENTION

[0019] The present invention provides a method for treating, reducing, inhibiting, or controlling neoplasia, tumor, or cancer in a subject undergoing tumor resection or immunotherapy, comprising administering a non-pathogenic, non-viable mycobacterium and, optionally, one or more chemotherapeutic agents. The method is based on the surprising discovery that administration of a non-pathogenic, heat-killed mycobacterium, optionally in combination with an additional chemotherapeutic agent, as neoadjuvant therapy prior to surgery or checkpoint inhibitor therapy (CPI) results in enhanced anti-tumor activity and / or more potent anti-tumor activity than surgery or CPI alone. Furthermore, treatment with mycobacteria has been shown to result in effective and durable pathological responses and survival in treated patients.

[0020] In a phase II clinical trial involving patients with pancreatic ductal adenocarcinoma (PDAC), non-pathogenic heat-killed mycobacteria administered in a multimodal neoadjuvant treatment regimen in combination with the chemotherapy drug gemcitabine were found to produce surprisingly effective and durable pathological responses and survival compared with gemcitabine alone, particularly in metastatic patients.

[0021] Thus, while several neoadjuvant therapies are known in the art to supplement resection or other cancer treatments, the invention disclosed herein provides specific immunomodulator-based neoadjuvant, periadjuvant, and adjuvant therapeutic protocols that are optimized to improve therapeutic efficacy, i.e., response, in a greater proportion of subjects undergoing surgery and / or checkpoint immunotherapy. To facilitate understanding of the invention, certain terms are first defined. Additional definitions are provided throughout the detailed description.

[0022] The terms "neoadjuvant therapeutic" or "neoadjuvant therapy," which may be used interchangeably with "preoperative therapy," refer to the administration of one or more therapeutic agents or modalities prior to a major treatment or surgery. The goal of such therapy is to effectively reduce the difficulty and complications of a more extensive surgical procedure and to enhance the overall effectiveness of said surgical procedure.

[0023] The terms "adjuvant therapy" and "periadjuvant therapy" are also used herein to refer to therapy administered during, or preferably after, surgery or treatment, or both before and after surgery or treatment, respectively.

[0024] "Tumor resection," sometimes simply referred to as "surgery" or "surgical procedure," refers to a procedure aimed at physically removing all or part of a tumor, preferably a primary tumor or lymph node, or an isolated single tumor or lymph node. Tumor resection is often used prior to chemotherapy or radiation and is often used in regimens that include adjuvant therapy. The term tumor resection is used to define various forms of tumor resection and may further include adjunctive surgery, including those of a lymphadenectomy nature, such as lymphadenectomy. The term tumor resection may also encompass surgery for localized metastatic tumors.

[0025] "Checkpoint inhibitors" are agents that act on surface proteins that are members of the TNF receptor superfamily or the B7 superfamily, including agents that bind to negative costimulatory (co-inhibitory) molecules selected from CTLA-4, PD-1, PD-L1, PD-L2, B7-H3, B7-H4, B7-H6, A2AR, IDO, TIM-3, BTLA, VISTA, TIGIT, LAG-3, CD40, KIR, CEACAM1, GARP, PS, CSF1R, CD94 / NKG2A, TDO, TNFR, DcR3, and / or their respective ligands (including PD-L1). "Blockers" are agents that bind to the above negative costimulatory molecules and / or their respective ligands. "Checkpoint inhibitors" and "blockers" are used interchangeably throughout.

[0026] Response Evaluation Criteria in Solid Tumors (based on RECIST) form the basis for progression-free survival (PFS) measurement, defining disease progression as an increase of at least 20% in the sum of the diameters of up to five target lesions (two lesions / organ) relative to the smallest sum within the study, an increase of at least 5 mm in absolute disease volume, or the appearance of a new lesion. A complete response is the disappearance of all target lesions, and a partial response (PR) is defined as at least a 30% reduction in the sum of target lesions. Stable disease is defined as not meeting either the criteria for progression or PR. PFS is defined as the time from randomization to progression or death. Time to progression is a related, less favorable, endpoint; death without progression is not counted as an event but is censored.

[0027] Non-pathogenic, non-viable mycobacteria, as defined herein, are components that stimulate innate and type I immunity, including Th1 and macrophage activation / polarization, cytotoxic cell activity, and, independently, downregulation of inappropriate anti-Th2 responses via immunomodulatory mechanisms. IMM-101 is an investigational systemic immunomodulator containing heat-killed Mycobacterium obuense. IMM-101 contains microbe-associated molecular patterns (MAMPs) that activate a distinct selection of pathogen recognition receptors (PRRs), including Toll-like receptors (TLR) 1 / 2, on dendritic cell (DC)-like innate immune cells (Bazzi et al. 2017, Galdon et al. 2019). Activation of immature DCs with IMM-101 leads to the biased maturation of activated cDC1s, which predominantly induce type 1 immune responses defined by the development and maturation of IFN-γ-, perforin-, and granzyme-producing CTLs (Galdon et al., 2019), which are required for effective tumor cell killing. IMM-101-induced cDC1 activation also leads to the development of activated IFN-γ-producing Th-1 cells, NK cells, NKT cells, and γδ-T cells (Fowler et al., 2014; Galdon et al., 2019), which can kill tumor cells by different mechanisms. Activated γδ-T cells are efficient antigen-presenting cells (Moser et al., 2017) and can further boost antitumor responses. IMM-101 also activates other innate immune cells, including monocytes, which mature into M1 macrophages that can enhance antitumor responses and suppress the formation of immunosuppressive M2 macrophages (Bazzi et al. 2015).

[0028] The terms "tumor," "cancer," and "neoplasia" are used interchangeably and refer to a cell or population of cells whose growth, proliferation, or survival is greater than that of a normal counterpart (e.g., a cell proliferative disorder or a cell differentiative disorder). Typically, the growth is uncontrolled. The term "malignant tumor" refers to the invasion of surrounding tissues. The term "metastasis" refers to the spread or spread of a tumor, cancer, or neoplasia to another site, location, or region within a subject, which site, location, or region is distinct from the primary tumor, lymph node, or cancer.

[0029] The term "non-metastatic" refers to the absence of distant metastasis or residual disease in a patient's primary tumor, lymph nodes, or cancer, as determined by 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG) scanning, CT, MRI, or positron emission tomography (PET).

[0030] The terms "Programmed Cell Death 1," "Programmed Cell Death 1," "PD-1 protein," "PD-1," and "PD1" are used interchangeably and encompass variants, isoforms, species homologs, and analogs of human PD-1 that share at least one epitope in common with PD-1.

[0031] As used herein, a "sub-therapeutic dose" means a dose of a therapeutic compound (e.g., an antibody) or a duration of treatment that is less than the usual or typical dose of the therapeutic compound or shorter than the duration of treatment when administered alone to treat cancer. Typical doses of known therapeutic compounds are known to those of skill in the art or can be determined through routine experimental studies.

[0032] The term "therapeutically effective amount" is defined as the amount of checkpoint inhibitor, preferably in combination with non-pathogenic, non-viable mycobacteria, that results in a reduction in the severity of cancer symptoms, an increase in the frequency and duration of cancer symptom-free periods, or prevention of functional impairment or disability due to the disease.

[0033] The term "effective amount" or "pharmaceutical-effective amount" refers to an amount of a drug sufficient to produce a desired biological or therapeutic result. The result can be the prevention, amelioration, palliative, relief, delay, and / or reduction of one or more signs, symptoms, or causes of cancer, or any other desired alteration of a biological system. With respect to cancer, an effective amount may include an amount sufficient to shrink a tumor and / or reduce the rate of tumor growth (e.g., tumor growth inhibition), or prevent or slow other unwanted cell proliferation. In some embodiments, an effective amount is an amount sufficient to delay the onset, prolong survival, or induce stabilization of a cancer or tumor. Preferably, therapeutic efficacy is measured by a reduction or stabilization of tumor size of one or more of said tumors as defined by RECIST 1.1, including stable disease (SD), complete response (CR), or partial response (PR) of the target tumor; and / or stable disease (SD) or complete response (CR) of one or more non-target tumors. Alternatively, therapeutic efficacy may be assessed by immune-related response criteria (irRC), iRECIST, or irRECIST, as known to those skilled in the art. Alternatively, therapeutic efficacy of the invention described herein may be indicated by complete or near-complete regression of pathology, preferably measured 3, 4, or 5 weeks or more after completion of surgery or the last administration of the mycobacterium.

[0034] In some embodiments, a therapeutically effective amount is an amount sufficient to prevent or delay recurrence. A therapeutically effective amount can be administered in one or more doses. A therapeutically effective amount of mycobacteria, alone or, preferably, in combination with surgery, pre- and / or post-operatively, can result in one or more of the following: (i) a reduction in cancer cell count; (ii) a reduction in tumor size; (iii) inhibition, delay, some slowing, preferably cessation of cancer cell invasion into peripheral organs; (iv) inhibition (i.e., some slowing, preferably cessation) of tumor metastasis; (v) inhibition of tumor growth; (vi) suppression or delay of tumor onset and / or recurrence; and / or (vii) some alleviation of one or more symptoms associated with cancer. For example, in the case of treating a tumor, a "therapeutically effective amount" can induce tumor regression of at least about 5%, such as at least about 10%, or about 20%, or about 60%, or more, relative to baseline measurements. Baseline measurements can be obtained from untreated subjects.

[0035] A therapeutically effective amount of mycobacteria alone, or preferably in combination with surgery pre- and / or post-operatively, can reduce tumor size or otherwise ameliorate symptoms in a subject. One of ordinary skill in the art can determine such an amount based on factors such as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected.

[0036] The term "immune response" refers to the actions of, for example, lymphocytes, antigen-presenting cells, phagocytes, granulocytes, and soluble macromolecules (including antibodies, cytokines, and complement) produced by such cells or the liver that selectively result in damage to, destruction of, or elimination of cancerous cells from the body.

[0037] The term "checkpoint inhibitor" or "immunotherapy" may further include the use of cells, viruses, lysates, vectors, genes, mRNA, DNA, nucleic acids, proteins, polypeptides, peptides, antibodies, bispecific antibodies, multispecific antibodies, ADCs (antibody drug conjugates), Fab fragments (Fab), F(ab')2 fragments, diabodies, triabodies, tetrabodies, probodies, single chain variable fragments (scFv), disulfide-stabilized variable fragments (dsFv), or other antigen-binding fragments thereof in the practice of the present invention.

[0038] The term "antibody", as used herein, includes whole antibodies and any antigen-binding fragment (ie, "antigen-binding portion") or single chain thereof, including monoclonal antibodies.

[0039] In addition to antibodies, other biomolecules may act as checkpoint inhibitors, including peptides or fusion proteins with binding affinity for appropriate targets.

[0040] "Non-viable" means that the mycobacterium has been microbiologically inactivated through specific cell-killing means. Methods that allow or enforce such non-viability may include heat sterilization, extended freeze-drying (Tolerys SA), irradiation with gamma radiation or electron beams, or exposure of the mycobacterium to chemicals such as formaldehyde. This preparation at the time of manufacture ensures that the organisms are free of known side effects from delivering live or attenuated organisms.

[0041] The terms "treatment" or "therapy" refer to the administration of an active agent with the intent to eliminate, cure, alleviate, relieve, alter, ameliorate, relieve, improve, or affect, in a statistically significant manner, a condition (e.g., a disease), the symptoms of a condition, or to prevent or delay the onset of symptoms, complications, or biochemical manifestations, or to arrest or inhibit further development of a disease, condition, or disorder.

[0042] As used herein, the term "subject" or "patient" is intended to encompass humans and non-human animals. Preferred subjects include human patients in need of an enhanced immune response. The method is particularly suitable for treating human patients with disorders treatable by enhancing a T cell-mediated immune response. In certain embodiments, the method is particularly suitable for treating cancer cells in vivo.

[0043] As used herein, the terms "co-administration," or "concomitantly," or "simultaneously" mean that administration occurs on the same day. The terms "sequential administration," or "sequentially," or "separately" mean that administration occurs on different days.

[0044] "Concurrent" administration, as defined herein, includes administration of the non-viable mycobacterium and one or more additional anti-cancer therapies or agents within about 2 hours or less, or about 1 hour or less, of each other. Preferably, "concurrent" administration refers to administration of the non-viable mycobacterium and one or more additional anti-cancer therapies or agents at the same time.

[0045] "Separate" administration, as defined herein, includes administering the non-viable mycobacterium and one or more additional anti-cancer treatments or agents more than about 12 hours, or more than about 8 hours, or more than about 6 hours, or more than about 4 hours, or more than about 2 hours apart.

[0046] "Sequential" administration, as defined herein, includes administering each of the non-viable mycobacterium and one or more additional anti-cancer therapies or agents in multiple aliquots and / or doses and / or on separate occasions. The non-viable mycobacterium may be administered to the patient before and / or after administration of the one or more additional anti-cancer therapies or agents. Alternatively, the non-viable mycobacterium continues to be administered to the patient after treatment with the one or more additional anti-cancer therapies or agents.

[0047] The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the indefinite article "a" or "an" should be understood to refer to "one or more" of any described or listed component.

[0048] As used herein, the term "about" means within an acceptable error range for a particular value, as determined by one of ordinary skill in the art, and will depend in part on how the value is measured or quantified, i.e., the limitations of the measurement system. For example, "about" can mean within one standard deviation or greater than one, according to practice in the art. Alternatively, "about" can mean a range of up to 20%. When a particular value is given in this application and claims, unless otherwise specified, the meaning of "about" should be considered to be within an acceptable error range for that particular value.

[0049] Mycobacterium vaccae (M. vaccae) and Mycobacterium obuense (M. obuense) have been shown to induce complex immune responses in the host. Treatment with these preparations stimulates innate and type I immunity, including Th1 and macrophage activation, and cytotoxic cell activity. These preparations also independently downregulate inappropriate Th2 responses through immunomodulatory mechanisms.

[0050] In the context of cancer, the formation of IFN-γ-producing CTLs is likely to be the most important outcome from IMM-101 treatment, as depletion of CD8+ T cells completely suppressed the observed antitumor effects of IMM-101 in a pancreatic cancer model.

[0051] The ability of IMM-101 to activate macrophages may be important not only for DC activation through the release of proinflammatory macrophage-derived cytokines (such as IL-12, which is necessary to bias DCs toward a type 1 immune response) but also for converting tumor-associated immunosuppressive type 2 macrophages into tumor-invasive type 1 macrophages, a feature also shown in the case of a similar heat-killed mycobacterium, Mycobacterium indicus pranii.

[0052] A key feature of IMM-101 is its ability to activate and mature DCs into a dendritic cell subclass known as cDC1 (i.e., DCs required for type 1 immune responses). Activation of sufficient numbers of cDC1s has been shown to be essential for CPI efficacy.

[0053] Preoperative short-term administration of checkpoint inhibitors in microsatellite instability-high (MSI) colorectal cancer has been shown to induce a high rate of pathological regression. A recently published small exploratory phase II trial (Chalabi et al. 2018, Immunotherapy of Cancer 29:8) showed that 6 weeks of preoperative administration of the CTLA-4 antibody ipilimumab and the PD-1 antibody nivolimumab resulted in complete or subtotal disease remission, suggesting that neoadjuvant therapy may be particularly effective in some cancer indications.

[0054] Thus, the present invention provides a protocol for using IMM-101 as a surprisingly favorable neoadjuvant or adjuvant therapy, with or without the use of other chemotherapy agents, to improve unfavorable prognosis in patients scheduled to undergo tumor resection or checkpoint inhibitor therapy for cancer. Such patients may include patients with colorectal cancer, particularly mismatch repair-deficient (dMMR) colorectal cancer with microsatellite instability (MSI).

[0055] In a further aspect of the invention, the cancer is determined to be microsatellite instability high (MSI) as measured by a PCR-based assay, and / or the cancer is subjected to IHC staining to analyze DNA mismatch repair (MMR) protein expression.

[0056] In one embodiment of the present invention, the non-pathogenic, non-viable mycobacterium comprises non-pathogenic, heat-killed mycobacterium. Exemplary mycobacterial species for use in the present invention include Mycobacterium vaccae, Mycobacterium thermoresistibile, Mycobacterium flavescens, Mycobacterium duvalii, Mycobacterium phlei, Mycobacterium obuense, Mycobacterium parafortuitum, Mycobacterium spp. ... ortuitum, Mycobacterium sphagni (M. sphagni), Mycobacterium aichiense (M. aichiense), Mycobacterium rhodesiae (M. rhodesiae), Mycobacterium neoaurum (M. neoaurum), Mycobacterium chubuense (M. chubuense), Mycobacterium tokaiense (M. tokaiense), Mycobacterium komossense (M. komossense), Mycobacterium aura Mycobacterium aurum (M. aurum), Mycobacterium w (Mw), Mycobacterium tuberculosis (M. tuberculosi), Mycobacterium microti (M. microti); Mycobacterium africanum (M. africanum); Mycobacterium kansasii (M. kansasii), Mycobacterium marinum (M. marinum); Mycobacterium simiae (M. simiae); Mycobacterium gastri (M. gastri); Mycobacterium nonchromogenicum (M. nonc hromogenicum); Mycobacterium terrae (M. terrae); Mycobacterium triviale (M. triviale); Mycobacterium gordonae (M. gordonae); Mycobacterium scrofulaceum (M. scrofulaceum); Mycobacterium paraffinicum (M. paraffinicum); Mycobacterium intracellulare (M. intracellulare); Mycobacterium avium (M. avium); Mycobacterium xenopi (M.xenopi; Mycobacterium ulcerans (M. ulcerans); Mycobacterium diernhoferi (M. diernhoferi), Mycobacterium smegmatis (M. smegmatis); Mycobacterium thamnopheos (M. thamnopheos); Mycobacterium flavescens (M. flavescens); Mycobacterium fortuitum (M. fortuitum); Mycobacterium peregrinum (M. peregrinum); Mycobacterium chelonei (M. chelonei); Mycobacterium paratuberculosis (M. paratuberculosis); Mycobacterium leprae (M. lepraemurium); and combinations thereof.

[0057] Non-pathogenic, non-viable Icobacteria include strains deposited under accession numbers NCTC11659 and related designations such as SRL172, SRP299, IMM-201, DAR-901, and the strain deposited as ATCC 95051 (Vaccae™), including Mycobacterium vaccae (M. vaccae); Mycobacterium obuense (M. obuense), M. paragordonae (strain 49061), Mycobacterium parafortuitum, M. paratuberculosis, M. brumae, M. aurum, M. indicus planii, M. indicus var. pranii, Mycobacterium w (Mw), Mycobacterium manresensis, Mycobacterium kyogaense (deposited as DSM107316 / CECT9546), Mycobacterium phlei, M. smegmatis, Mycobacterium tuberculosis Aoyama B or H37Rv, RUTI, MTBVAC, BCG, VPM1002BC, SMP-105, mifamurtide, Z-100, and combinations thereof, and preferably the Mycobacterium obuense strain deposited under the Budapest Treaty under accession number NCTC13365.

[0058] In another most preferred embodiment, the non-pathogenic, non-viable mycobacterium is Mycobacterium vaccae, including that deposited under NCTC 11569, or Mycobacterium obuense, such as that deposited under NCTC 13365. In another preferred embodiment, the non-pathogenic, non-viable mycobacterium is a rough form. In a preferred embodiment of the present invention, the non-pathogenic, non-viable mycobacterium is a rough form, preferably a rough form of Mycobacterium obuense.

[0059] In another embodiment of the present invention, the non-pathogenic, non-viable mycobacterium is rough and / or whole cell, preferably a rough strain of Mycobacterium obuense deposited under the Budapest Treaty under accession number NCTC13365.

[0060] In another embodiment of the present invention, the non-pathogenic, non-viable mycobacteria have been inactivated by heat, such as autoclaving, extended freeze-drying, chemical exposure, such as formaldehyde, or irradiation, such as gamma irradiation or electron beam irradiation.

[0061] In another embodiment of the invention, the non-pathogenic, non-viable mycobacterium does not include live attenuated BCG.

[0062] In another embodiment, the non-pathogenic, non-viable mycobacteria are in a rough form and / or presented as fractions, fragments, subcellular components, lysates, homogenates, sonicates, or in the form of substantially whole cells.

[0063] In a preferred embodiment of the invention, the non-pathogenic, non-viable mycobacteria, preferably Mycobacterium obuense, are in the form of substantially whole cells, such that more than 50% or more of the mycobacteria in the suspension are greater than 1-10 microns in diameter as measured by laser diffraction (e.g., D50 value or average particle size), or are in a form that has not been exposed to conditions such as high pressure treatment to induce significant cell lysis.

[0064] As will be appreciated by those skilled in the art, for example, rough forms of M. obuense lack cell surface-associated glycopeptidolipids (GPLs) and are therefore characterized by a non-motile, non-biofilm-forming, rough morphology, as described by Roux et al. 2016, Open Biol 6: 160185. The amount of mycobacteria administered to a patient in the present invention will be sufficient to induce a protective immune response in the patient, enabling the patient's immune system to mount an effective immune response.

[0065] In another most preferred embodiment, the cancer is determined to be colorectal cancer (CRC), and the cancer or tumor is in the ascending, descending, and / or descending colon, and / or rectum.

[0066] In some embodiments, the cancer is determined to be colon cancer, optionally metastatic colon cancer.

[0067] In other embodiments, the cancer is determined to be rectal cancer, optionally metastatic rectal cancer.

[0068] The amount of mycobacteria administered to a patient is sufficient to induce an immune response in the patient such that the patient's immune system is able to mediate an effective immune response against the cancer or tumor. In certain embodiments of the invention, a container means is provided containing an effective amount of mycobacteria for use in the invention, typically in the amount of 10 3~10 11 organisms, preferably 10 4 ~10 10 organisms, more preferably 10 6 ~10 10 organisms, and even more preferably 10 6 ~10 9 Most preferably, the amount of mycobacteria for use in the present invention is 10 7 ~10 9 Typically, the compositions of the present invention are administered in amounts of 10 8 ~10 9 The dosage may be administered in a dose of cells. Alternatively, the dosage may be 0.0001 mg to 5 mg or 0.001 mg to 5 mg of organisms, preferably 0.01 mg to 2 mg or 0.1 mg to 2 mg of organisms, for example, about 0.5 mg or about 1 mg or about 0.5 mg or about 1 mg of organisms. The dosage may be formulated as a suspension or a dry preparation.

[0069] In certain embodiments of the invention, the amount of non-pathogenic, non-viable mycobacteria administered is 0.0001 mg to 1 mg per unit dose, and optionally the unit dose is administered on two or more separate occasions separated by at least 7 days or more, for example, on each of days 0, 14 (± 1, 3, 5, or more), and optionally on day 30 (± 5, 7, 10, or more) or day 45 (± 7, 10, or 14, or more).

[0070] In some embodiments, the amount of non-pathogenic, non-viable mycobacterium administered may be 0.0001 mg to 1 mg per dose, and the doses may be administered 1, 2, 3, 4, 5, 6, 10, 20 or more times over a period of days, weeks or months, and preferably the mycobacterium is M. obuense.

[0071] In other embodiments of the invention, the amount of non-pathogenic, non-viable mycobacteria administered may be 0.0001 mg to 1 mg per dose, which initially includes a single injection of 1 mg into one deltoid muscle, or two injections of 0.5 mg in each deltoid muscle, or two injections of 1.0 mg in each deltoid muscle, followed by a second dose of 0.5 mg or 1.0 mg 7 days, 14 days, or more later.

[0072] In certain embodiments of the invention, the amount of non-pathogenic, non-viable mycobacteria administered is 0.0001 mg to 1 mg per unit dose, such as about 0.5 to about 1 mg, and the unit doses are administered on two or more separate occasions separated by at least 7 days or more prior to surgery, for example, on days -35, -21, and -5 relative to surgery (i.e., prior to surgery), whereby the day -35 dose is 1 mg, the day -21 dose is 0.5 mg, and the day -5 dose is 0.5 mg. The checkpoint therapy, such as an anti-PD-L1 monoclonal antibody, preferably atezolizumab, pembrolizumab, or cemiplimab, may be administered on the same day as or between the unit doses of mycobacteria, for example, on days -28 and -7 relative to surgery (i.e., prior to surgery).

[0073] In another embodiment of the invention, the amount of non-pathogenic, non-viable mycobacteria administered is 0.0001 mg to 1 mg per unit dose, for example, about 0.5 to about 1 mg, and the unit doses are administered on two or more separate occasions separated by at least 7 days or more after surgery, for example, on days 21, 35, 49, and thereafter after surgery, whereby the dose on day 21 is 1 mg, the dose on day 35 is 0.5 mg, and the doses on days 49 and thereafter are 0.5 mg. The checkpoint therapy, such as an anti-PD-L1 monoclonal antibody, preferably atezolizumab, pembrolizumab, or cemiplimab, may be administered on the same day as or between the unit doses of mycobacteria, for example, on days 28, 42, 56, and thereafter after surgery.

[0074] In yet another embodiment of the invention, the amount of non-pathogenic, non-viable mycobacteria administered is 0.0001 mg to 1 mg per unit dose, for example, about 0.5 to about 1 mg, and the unit doses are administered on two or more separate occasions separated by at least 7 days or more prior to surgery, for example, on days -35, -21, and -5 relative to surgery (i.e., prior to surgery), and optionally, the day -35 dose is 1 mg, the day -21 dose is 0.5 mg, and the day -5 dose is 0.5 mg. The checkpoint therapy, such as an anti-PD-L1 monoclonal antibody, preferably atezolizumab, pembrolizumab, or cemiplimab, may be administered on the same day as or during the unit dose of mycobacterium, such as on day -28 and day -7 relative to (i.e., prior to) the surgery, and unit doses are administered on two or more separate occasions after surgery separated by at least 7 days or more, for example on each of days 21, 35, 49, and thereafter after the surgery, optionally wherein the dose on day 21 is 1 mg, the dose on day 35 is 0.5 mg, and the doses on days 49 and thereafter are 0.5 mg.

[0075] A checkpoint therapy, such as an anti-PD-L1 monoclonal antibody, preferably atezolizumab, pembrolizumab, or cemiplimab, may be administered on the same day as the unit dose of mycobacterium, or during the same period, for example, on days 28, 42, 56, and thereafter after the surgery. The present invention may be used to treat neoplastic diseases, such as solid or non-solid cancers.

[0076] As used herein, "treatment" includes the prevention, reduction, control, and / or inhibition of neoplastic disease, including the regression or stabilization of a primary tumor and / or the regression or stabilization of one or more metastases, or the prevention or inhibition of one or more metastases or micrometastases.

[0077] Neoplasias, tumors, and cancers include benign, malignant, metastatic, and non-metastatic types, and include neoplasias, tumors, or cancers of any stage (I, II, III, IV, or V) or grade (G1, G2, G3, etc.), or neoplasias, tumors, cancers, or metastases that are ongoing, progressing, stable, or in remission. Preferably, cancers at the time of initiating the practice of the present invention are clinically defined as stage I, stage II, or stage II. Cancers that may be treated according to the present invention include, but are not limited to, bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal tract, gums, head, kidney, liver, lung, nasopharynx, cervix, ovary, prostate, skin, stomach, testicles, tongue, or uterus. In addition, the cancer may specifically be of the following histological types, but is not limited to: neoplasm, malignant carcinoma; undifferentiated carcinoma; giant spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyps; familial polyposis coli adenocarcinoma; solid tumor; carcinoid tumor, malignant bronchioloalveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophilic carcinoma; acidophilic adenocarcinoma; basophilic carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary follicular adenocarcinoma; non-encapsulated sclerosing carcinoma; adrenocortical carcinoma; endometrioid carcinoma carcinoma); skin adnexal carcinoma; apocrine gland carcinoma; sebaceous gland carcinoma; earwax gland carcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystic carcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; invasive ductal carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; Paget's disease of the breast; acinic cell carcinoma; adenosquamous carcinoma; adenocarcinoma with squamous metaplasia; thymoma; malignant ovarian stromal tumor, malignant theca cell tumor, malignant granulosa cell tumor, malignant Sertoli stromal cell tumor, malignant Sertoli cell carcinoma; Leydig cell carcinoma Cystoma, malignant lipocytoma, malignant paraganglioma, malignant extramammary paraganglioma, malignant pheochromocytoma; hemangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant pigmented nevus; metastatic melanoma, lentigo maligna, lentigo maligna melanoma, cutaneous squamous cell carcinoma, nodular melanoma, acral lentiginous melanoma, desmoplastic melanoma, epithelioid cell melanoma; blue nevus, malignant sarcoma; fibrosarcoma; fibrous histiocytoma, malignant myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma;Embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; undifferentiated pleomorphic sarcoma; stromal sarcoma; mixed tumor; mixed Müllerian tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymal cell tumor, malignant Brenner tumor, malignant phyllodes tumor, malignant synovial sarcoma; mesothelioma, malignant dysgerminoma; embryonal carcinoma; malignant teratoma; malignant ovarian stromal tumor; choriocarcinoma; mesonephroma, malignant angiosarcoma; hemangioendothelioma, malignant Kaposi's sarcoma; hemangiopericytoma, malignant lymphangiosarcoma; osteosarcoma; parosteal Osteosarcoma; Chondrosarcoma; Chondroblastoma, malignant mesenchymal chondrosarcoma; Giant cell tumor of bone; Ewing's sarcoma; Odontogenic tumor, malignant ameloblastic odontosarcoma; Ameloblastoma, malignant ameloblastic fibrosarcoma; Pinealoma, malignant chordoma; Glioma, malignant ependymoma; Astrocytoma; Protoplasmic astrocytoma; Fibrous astrocytoma; Astroblastoma; Glioblastoma multiforme; Oligodendroglioma; Oligodendroglioma; Primitive neuroectodermal neuroectodermal); cerebellar sarcoma; ganglionic blastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant neurofibrosarcoma; schwannoma, malignant granular cell tumor, malignant lymphoma; Hodgkin's disease; Hodgkin's lateral granuloma; malignant lymphoma, small lymphocytic lymphoma, diffuse large cell type; malignant follicular lymphoma; mycosis fungoides; other specified non-Hodgkin's lymphoma; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia. Preferably, the cancer is selected from bladder cancer (including non-muscle invasive bladder cancer), prostate cancer, liver cancer, kidney cancer, lung cancer, breast cancer, colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, brain cancer (including glioblastoma), hepatocellular carcinoma, lymphoma, leukemia, gastric cancer, cervical cancer, ovarian cancer, thyroid cancer, melanoma, head and neck cancer, skin cancer, and soft tissue sarcoma, and / or other forms of carcinoma;

[0078] More preferably, the cancer is pancreatic cancer, colorectal cancer, brain cancer, prostate cancer, skin cancer, soft tissue sarcoma, osteosarcoma, lung cancer, or ovarian cancer, including pancreatic ductal adenocarcinoma (PDAC).

[0079] In some embodiments of the present invention, early-stage cancer is defined by a staging system, such as the TNM system. The TNM system uses an alphanumeric code to represent the stage of cancer originating from a solid tumor. T represents various aspects of the original primary tumor, including size and growth; N represents potentially involved adjacent or regional lymph nodes; and M represents the extent of the tumor, i.e., the level of metastasis. The TX classification conveys to those skilled in the art that the tumor is not measurable; TO represents no evidence of a primary tumor; T1, T2, T3, and T4 represent sequential numbers representing increasing tumor size and / or tumor growth or the amount of spread to nearby structures, with higher T numbers representing greater tumor and / or tumor growth and spread. The NX classification similarly means that nearby lymph nodes could not be evaluated; NO means that nearby lymph nodes do not contain cancer; and N1, N2, and N3 represent increasing size, location, and / or number of affected nearby lymph nodes, respectively. Finally, M0 means that there is no evidence of distant spread of the cancer or that the tumor is not metastatic, while M1 means that the cancer has spread and metastasized.

[0080] In a preferred embodiment, early stage cancer is specifically defined by T being T1-T4, optionally M being M0, while N may be any classification such as N0, N1, or N2. Alternatively, the cancer is clinically defined as stage I, II, or III. In other words, cancer is defined by recorded size and growth of any size, and further, optionally, the tumor is non-metastatic.

[0081] In further preferred embodiments or methods of the invention, the patient does not present with metastases to any organs distant from the primary tumor, but may present with metastases to one or more lymph nodes close to the primary neoplasm or primary tumor and / or to one or more nearby organs, or the patient does not present with macroscopic residual disease following tumor resection, as indicated by an R2 resection status.

[0082] In a further preferred embodiment or method of the invention, the patient is clinically defined as non-metastatic.

[0083] In a further preferred embodiment or method of the present invention, the neoplasia, tumor, or cancer is related to a sarcoma, preferably a soft tissue sarcoma or a non-soft tissue sarcoma. Particularly preferred non-soft tissue sarcomas include osteosarcoma (osteosarcoma, Ewing's sarcoma) and chondrosarcoma. Particularly preferred sarcomas include pleomorphic undifferentiated sarcoma (UPS), angiosarcoma, leiomyosarcoma, non-uterine leiomyosarcoma, dedifferentiated liposarcoma (DDL), synovial sarcoma, rhabdomyosarcoma, epithelioid sarcoma, myxoid liposarcoma, alveolar soft part sarcoma, parachordoma / myoepithelioma, pleomorphic liposarcoma, extraskeletal myxoid chondrosarcoma, or malignant peripheral nerve sheath tumor. The patient may be under 50 years of age, between 20 and 30 years of age, a teenager or young adult (under 16 years of age), or a child (0-14 years of age). Optionally, the one or more sarcomas exhibit increased staining / expression of PD-L1 or PD-1. Optionally, the non-viable mycobacterium and / or checkpoint inhibitor and / or costimulatory conjugate are administered via intratumoral, peritumoral, perilesional, or intralesional administration.

[0084] The present invention relates to cancer patients who have undergone or will undergo tumor resection or checkpoint inhibitor therapy. The term "will undergo" may refer to a patient who has been counseled and / or managed to undergo said tumor resection or checkpoint inhibitor therapy as part of a health management and / or care plan protocol. In some embodiments, the immunomodulatory agents for use in the present invention may be used in the treatment, reduction, inhibition, or control of early stage cancer in patients who will undergo tumor resection or checkpoint inhibitor therapy for up to one year in the future. In other embodiments, the patient may be one who will undergo tumor resection or checkpoint inhibitor therapy for up to six months in the future. In a preferred embodiment, the patient may be one who will undergo tumor resection or checkpoint inhibitor therapy for up to six weeks in the future.

[0085] The present invention relates to a subject who has undergone or will undergo checkpoint inhibitor therapy, which may include administration of one or more blocking agents selected from cells, proteins, peptides, antibodies, ADCs (antibody drug conjugates), Fab fragments (Fab), F(ab')2 fragments, diabodies, triabodies, tetrabodies, probodies, single-chain variable fragments (scFv), disulfide-stabilized variable fragments (dsFv), or other antigen-binding fragments thereof, directed against CTLA-4, PD-1, PD-L1, PD-L2, B7-H3, B7-H4, B7-H6, A2AR, IDO, TIM-3, BTLA, VISTA, TIGIT, LAG-3, CD40, KIR, CEACAM1, GARP, PS, CSF1R, CD94 / NKG2A, TDO, TNFR, DcR3, and combinations thereof.

[0086] In embodiments of the invention, checkpoint blockade therapy may involve administration of said one or more blocking agents in sub-therapeutic amounts and / or for sub-therapeutic periods.

[0087] In an embodiment of the invention, the one or more blocking agents are ipilimumab, nivolumab, pembrolizumab, atezolizumab, BI754091 (anti-PD-1 agent), bavituximab (anti-PS IgG3 monoclonal antibody), vintrafusp alfa, dostallimab, durvalumab, tremelimumab, spartalizumab, avelumab, sintilimab, toripalimab, prolgolimab, tislelizumab, camrelizumab, MGA012, MGD013 (now known as tebotelimab), MGD019, nimotuzumab, enoblitzumab, MGD009, MGC018, MEDI0680, miptenalimab (BI754111, anti-LAG-3 agent), PDR001, FAZ053, TSR022, MBG453, leratolimab (BMS986016), LAG525 (IMP701) , IMP321 (eftilagimod alfa), REGN2810 (cemiplimab), REGN3767, pexidartinib (PLX3397), LY3022855, FPA008, BLZ945, GDC0919, epacadostat, emactuzumab (RG1755 targeting CSF-1R), FPA150, indoximid, BMS986205, CPI-444, MEDI9447, PBF509, FS118 (bispecific for LAG-3 and PD-L1), lirilumab, Sym023, TSR-022, A2Ar inhibitors (e.g., EOS100850, AB928), NKG2A inhibitors such as monalizumab, and combinations thereof.

[0088] In an embodiment of the invention, the one or more blocking agents are preferably ipilimumab and / or nivolumab.

[0089] In embodiments of the invention, co-stimulatory checkpoint therapy comprises administration of one or more conjugates selected from utomilumab, urelumab, MOXR0916, PF04518600, MEDI0562, GSK3174988, MEDI6469, RO7009789, CP870893, BMS986156, GWN323, JTX-2011, varlilumab, MK-4166, NKT-214, and combinations thereof.

[0090] In an embodiment of the invention, the one or more blocking agents or checkpoint inhibitors is most preferably atezolizumab.

[0091] In an embodiment of the invention, checkpoint inhibitor therapy includes any of a variety of antibodies, including cells, proteins, peptides, antibodies, ADCs (antibody drug conjugates), Fab fragments (Fab), F(ab')2 fragments, diabodies, tribodies, antibodies against CTLA-4, PD-1, PD-L1, PD-L2, B7-H3, B7-H4, B7-H6, A2AR, IDO, TIM-3, BTLA, VISTA, TIGIT, LAG-3, CD40, KIR, CEACAM1, GARP, PS, CSF1R, CD94 / NKG2A, TDO, TNFR, DcR3, and combinations thereof. The present invention includes administering one or more blocking agents selected from abody, tetrabody, probody, single-chain variable region fragment (scFv), disulfide-stabilized variable region fragment (dsFv), or other antigen-binding fragments thereof in combination with non-viable mycobacteria to reduce or inhibit metastasis of the primary tumor or primary cancer to other sites, or the formation or establishment of metastatic tumors or metastatic cancers at other sites distal to the primary tumor or primary cancer, thereby inhibiting or reducing tumor or cancer recurrence or tumor or cancer progression.

[0092] In an embodiment of the present invention, there is provided a non-pathogenic, non-viable mycobacterium for use in the adjuvant, neoadjuvant, or periadjuvant treatment, reduction, inhibition, or control of one or more tumors in a subject who has undergone or will undergo tumor resection or checkpoint inhibitor therapy, wherein the non-pathogenic, non-viable mycobacterium may induce a strong and durable immune response with enhanced therapeutic efficacy compared to surgery or therapy alone, preferably as measured by a reduction or stabilization of tumor size of one or more of said tumors, as defined by RECIST 1.1, or iRRC, or iRECIST, or irrRECIST, including stable disease (SD), complete response (CR), or partial response (PR) of the target tumor; and / or stable disease (SD) or complete response (CR) of one or more non-target tumors.

[0093] In some embodiments, a checkpoint inhibitor therapy of the present invention may be a costimulatory checkpoint therapy comprising administration of one or more conjugates selected from cells, proteins, peptides, antibodies, ADCs (antibody drug conjugates), Fab fragments (Fab), F(ab')2 fragments, diabodies, triabodies, tetrabodies, probodies, single-chain variable fragments (scFv), disulfide-stabilized variable fragments (dsFv), or other antigen-binding fragments thereof, against CD27, CD28, CD40, CD122, CD137, OX40, GITR, ICOS, and combinations thereof.

[0094] In embodiments of the invention, costimulatory checkpoint therapy comprises administration of one or more conjugates selected from utomilumab, urelumab, MOXR0916, PF04518600, MEDI0562, GSK3174988, MEDI6469, RO7009789, CP870893, BMS986156, GWN323, JTX-2011, varlilumab, MK-4166, NKT-214, and combinations thereof.

[0095] In some further embodiments, checkpoint blockade therapy may include administration of two or more blocking agents directed against any one of the following receptor targeting combinations: CTLA-4 and PD-1, CTLA-4 and PD-L1, PD-1 and LAG-3, or PD-1 and PD-L1.

[0096] Specific suitable combinations include durvalumab + tremelimumab, nivolumab + ipilimumab, pembrolizumab + ipilimumab, MEDI0680 + durvalumab, PDR001 + FAZ053, nivolumab + TSR022, PDR001 + MBG453, nivolumab + BMS986016, PDR001 + LAG525, pembrolizumab + IMP321, REGN2810 (cemiplimab) + REGN3767, and other suitable combinations.

[0097] In some embodiments, checkpoint inhibitor therapy may further include costimulatory checkpoint therapy for any one of the following combinations: CTLA-4 and CD40, CTLA-4 and OX40, CTLA-4 and IDO, OX-40 and PD-L1, PD-1 and OX-40, CD27 and PD-L1, PD-1 and CD137, PD-L1 and CD137, OX-40 and CD137, CTLA-4 and IDO, PD-1 and IDO, PD-L1 and IDO, PD1 and A2AR, PD-L1 and A2AR, PD1 and GITR, PD-L1 and GITR, PD1 and ICOS, PD-L1 and ICOS, PD1 and CD27, PD-L1 and CD27, PD1 and CD122, PD-L1 and CD122, PD1 and CSF1R, PD-L1 and CSF1R, and other such suitable combinations.

[0098] Specific preferred combinations include avelumab + utomilumab, nivolumab + urelumab, pembrolizumab + utomilumab, atezolizumab + MOXR0916 ± bevacizumab, avelumab + PF-04518600, durvalumab + MEDI0562, pembrolizumab + GSK3174998, tremelimumab + durvalumab + MEDI6469, tremelimumab + MEDI0562, utomilumab + PF-04518600, atezolizumab + RO7009789, tremelimumab + CP870893, nivolumab + BMS986156, PDR001 + GWN323, and nivolumab + JTX. -2011, atezolizumab + GDC0919, ipilimumab + epacadostat, ipilimumab + indoximid, nivolumab + BMS986205, pembrolizumab + epacadostat, atezolizumab + CPI-444, durvalumab + MEDI9447, PDR001 + PBF509, nivolumab + varlilumab, atezolizumab + varlilumab, nivolumab + NKTR-214, durvalumab + pexidartinib (PLX3397), durvalumab + LY3022855, nivolumab + FPA008, pembrolizumab + pexidartinib, PDR001 + BLZ945, and tremelimumab + LY3022855.

[0099] In another embodiment, the checkpoint inhibitor therapy comprises administration of a blocking agent that is an antibody selected from the group consisting of AMP-224 (Amplimmune, Inc.), BMS-986016 (leratolimab), or MGA-271, and combinations thereof.

[0100] In one embodiment, the costimulatory checkpoint therapy upregulates the cellular immune system, and the costimulatory checkpoint therapy is a CD137 agonist, including but not limited to BMS-663513 (urelumab, an anti-CD137 humanized monoclonal antibody agonist, Bristol-Myers Squibb); a CD40 agonist, such as CP-870,893 (a-CD40 humanized monoclonal antibody, Pfizer); an OX40 (CD134) agonist (e.g., an anti-OX40 humanized monoclonal antibody, AgonOx, and and U.S. Patent No. 7,959,925), and MEDI0562, a humanized OX40 agonist from AstraZeneca; MEDI6469, a murine OX4 agonist; and MEDI6383, an OX40 agonist; or CD27 agonists such as CDX-1127 (a-CD27 humanized monoclonal antibody, Celldex). Suitable anti-GITR antibodies include TRX518 (Tolerx), MK-1248 (Merck), and CK-302. Suitable anti-4-1BB antibodies for use in the present invention include PF-5082566 (Pfizer).

[0101] The most preferred TLR3 agonist for use in the present invention is lintatolimod (Ampligen).

[0102] In an embodiment of the invention, checkpoint blockade therapy and / or costimulatory checkpoint therapy acts synergistically with mycobacteria.

[0103] In some embodiments of the present invention, treating, reducing, inhibiting, or controlling early stage cancer further comprises administering one or more additional anti-cancer treatments or agents.

[0104] The one or more additional anti-cancer treatments or agents may be adoptive cell therapy, surgery, chemotherapy, radiation therapy, hormone therapy, checkpoint inhibitor therapy, small molecule therapy such as metformin, receptor kinase inhibitor therapy such as tyrosine kinase inhibitor therapy, hyperthermia, phototherapy, radiofrequency ablation (RFA), anti-angiogenic therapy, cytokine therapy, cryotherapy, biological therapy, HDAC inhibitors such as OKI-179, BRAF inhibitors, MEK inhibitors, EGFR inhibitors, VEGF inhibitors , P13Kδ inhibitors, PARP inhibitors, mTOR inhibitors, hypomethylating agents, oncolytic viruses, TLR agonists including TLR2 agonists, TLR3 agonists, TLR4 agonists, TLR7 agonists, TLR8 agonists, or TLR9 agonists, or TLR5 agonists such as MRx0518 (4D Pharma), STING agonists (including MIW815 and SYNB1891), mifamurtide, and cancer vaccines such as GVAX or CIMAvax, and combinations thereof.

[0105] In another embodiment of the present invention, the one or more additional anti-cancer therapies provide immunogenic cell death therapy, as described in International Patent Application No. 2013 / 07998. This therapy induces immunogenic cell death in tumors, including apoptosis (type 1), autophagy (type 2), and necrosis (type 3), with the release of tumor antigens, which can induce immune responses, including activation of cytotoxic CD8+ T cells and NK cells, and can act as targets, including making the antigens accessible to dendritic cells. This immunogenic cell death therapy is not intended to completely remove or eradicate tumors, but can be performed at a suboptimal level to induce necrosis of some tumor cells or tumor tissue (i.e., a non-curative treatment). Those skilled in the art will be able to assess the extent of treatment necessary to achieve this, depending on the procedure used, the patient's age, the state of the disease, and, in particular, the size and location of the tumor or metastasis. Particularly preferred treatments include microwave irradiation, targeted radiation therapy such as stereotactic body radiotherapy (SABR), embolization, cryotherapy, ultrasound, high intensity focused ultrasound, Cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrocautery heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser light irradiation, and combinations thereof.

[0106] In another embodiment of the invention, TLR agonists include MRx0518 (4D Pharma), mifamurtide (Mepact), krestin (PSK), IMO-2125 (tilsotolimod), CMP-001, MGN-1703 (lefitolimod), entrimod, lintatolimod (Ampligen), SD-101, GS-9620, imiquimod, resiquimod, MEDI4736, polyinosinic-polycytidine, CPG7909, DSP-0509, VTX-2337 (motolimod), MEDI9197, NKTR-262, G100, or PF-3512676, and combinations thereof.

[0107] In another embodiment of the invention, chemotherapy comprises administration of one or more agents selected from cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, mustine, vincristine, procarbazine, prednisolone, bleomycin, vinblastine, dacarbazine, etoposide, cisplatin, epirubicin, capecitabine, leucovorin, folinic acid, carboplatin, oxaliplatin, gemcitabine, FOLIFIRINOX, modified FOLIFIRINOX, FOLFOX, paclitaxel, pemetrexed, irinotecan temozolomide, and combinations thereof.

[0108] In another embodiment of the invention, the treatment comprises atezolizumab in combination with folinic acid, fluorouracil, and oxaliplatin (Folfox) and bevacizumab, preferably as adjuvant, neoadjuvant, or periadjuvant therapy in patients with stage III dMMR and / or MSI-high colorectal cancer (CRC). Alternatively, patients may receive atezolizumab, Folfox, and bevacizumab, with or without mycobacterium, for six months, followed by atezolizumab (azetolizumab), with or without bevacizumab and / or with or without mycobacterium, for an additional six or more months.

[0109] In another embodiment of the invention, the treatment comprises atezolizumab in combination with folinic acid, fluorouracil, and oxaliplatin (Folfox), preferably as adjuvant, neoadjuvant, or periadjuvant therapy in patients with stage III dMMR and / or MSI-high CRC. Alternatively, patients may receive atezolizumab and Folfox, with or without mycobacterium, for six months.

[0110] In another embodiment of the invention, the combination is suitable for the treatment of pMMR-MSI-low CRC tumours, i.e. mismatch repair-deficient and microsatellite-low instability tumours, and includes a combination of checkpoint inhibitors such as pembrolizumab and / or atezolizumab, or durvalumab and / or tremelimumab, with or without folfox, in combination with mycobacterium. Other combinations include atezolizumab and bevacizumab together with mycobacterium.

[0111] In another embodiment of the invention, the combination is suitable for the treatment of pMMR-low MSI CRC tumours and the non-pathogenic, non-viable mycobacteria are administered in combination with one or more of the following combinations: RFA and / or EBRT and / or pembrolizumab; RFA and / or durvalumab and / or tremelimumab; atezolizumab and / or bevacizumab and / or folfox; atezolizumab and cobimetinib; nivolumab + ipilimumab + cobimetinib; atezolizumab + cobimetinib + bevacizumab; atezolizumab + CEA-BTC antibody; pembrolizumab + indoximod; nivolumab + epacadostat; durvalumab + pexidartinib.

[0112] In another embodiment of the invention, the combination comprises either radiofrequency ablation therapy (RFA) or external beam radiation therapy (EBRT) in CRC patients with a checkpoint inhibitor such as pembrolizumab and / or atezolizumab, or durvalumab and / or tremelimumab, in combination with Mycobacterium.

[0113] In another embodiment of the invention, the adjuvant, neoadjuvant, or periadjuvant therapy disclosed herein is applied to patients with stage III dMMR and / or MSI-high colorectal cancer or colon or rectal cancer, said patients having an ECOG performance status of 0 (PS0), 1 (PS1), or PS1-, or 2 (PS2).

[0114] In another embodiment of the invention, the adjuvant, neoadjuvant, or periadjuvant therapy disclosed herein is administered to patients presenting with an ECOG performance status of 0 (PS0), 1 (PS1), or PS1-, or 2 (PS2), wherein said performance status value is the same or improved when assessed postoperatively or at the end of treatment.

[0115] In another embodiment of the present invention, the adjuvant, neoadjuvant, or periadjuvant therapy disclosed herein is applied to patients with stage III pMMR / low-MSI colorectal cancer or colon cancer or rectal cancer, i.e., mismatch repair-deficient and low-microsatellite instability tumors in patients with colorectal cancer or colon cancer or rectal cancer, said patients having an ECOG performance status of 0 (PS0), 1 (PS1), or PS1-, or 2 (PS2).

[0116] In some preferred embodiments, the one or more additional anti-cancer treatments or agents may comprise a checkpoint inhibitor, such as ipilimumab, nivolumab, pembrolizumab, atezolizumab, vintrafusp alfa, dostallimab, durvalumab, tremelimumab, spartalizumab, avelumab, sintilimab, toripalimab, prolgolimab, tislelizumab, camrelizumab, MGA012, MGD013, MGD019, enoblitzumab, MGD009, MGC018, MEDI0680, PDR 001, FAZ053, TSR022, MBG453, leratolimab (BMS986016), LAG525, IMP321, REGN2810 (cemiplimab), REGN3767, pexidartinib, LY3022855, FPA008, BLZ945, GDC0919, epacadostat, indoximid, BMS986205, CPI-444, MEDI9447, PBF509, and combinations thereof.

[0117] In another embodiment of the invention, the one or more additional anti-cancer treatments or agents and / or mycobacteria are administered intratumorally, intraarterially, intravenously, intravascularly, intrapleurally, intraperitoneally, intratracheally, intranasally, intralymph node, transpulmonary, intrathecally, intramuscularly, endoscopically, intralesionally, perilesionally, peritumorally, percutaneously, subcutaneously, topically, stereotactically, orally, or by direct injection or perfusion.

[0118] Suitable dose ranges and administration protocols for each of the one or more additional anti-cancer treatments or agents will be understood within the art. By way of example, a suitable administration protocol for atezolizumab may be 1200 mg every three weeks. In some embodiments, atezolizumab may be administered intravenously at a dose of 1200 mg every three weeks for up to 12 months or longer. In another embodiment, atezolizumab may be administered intravenously every three weeks for 6-8 weeks prior to tumor resection or further checkpoint inhibitor therapy.

[0119] In some embodiments, atezolizumab may be administered intravenously at a dose of 1200 mg every 3 weeks (±3 days) starting 7 and 28 days before tumor resection, and mycobacterium may be administered on the same day or on a different day, such as 35 and / or 21 and / or 5 days before tumor resection. Alternatively, atezolizumab may be administered intravenously at a dose of 840 mg every 2 weeks (±3 days) starting 28 days after tumor resection, and mycobacterium may be administered on the same day or on a different day, such as 21, 35, 42, and later (et seq) after the tumor resection.

[0120] In another embodiment, atezolizumab may be administered intravenously at a dose of 1200 mg every 3 weeks (±3 days) starting 7 and 28 days before tumor resection, and mycobacterium may be administered on the same day or on different days, such as 35, 21, and 5 days before tumor resection. Additionally, atezolizumab may be administered intravenously at a dose of 840 mg every 2 weeks (±3 days) starting 28 days after tumor resection, and mycobacterium may be administered on the same day or on different days, such as 21, 35, 42, and later (et seq) after the tumor resection.

[0121] In a preferred embodiment of the invention, the tumor resection results in tumor margins as defined according to the AJCC 8th edition, such as R0 margins, where no cancer cells are visible under a microscope at the primary tumor site; or R1 margins, where cancer cells are present under a microscope at the primary tumor site; or R2 margins, where macroscopic residual tumor is found at the primary tumor site and / or in the regional lymph nodes.

[0122] In another embodiment, the combination or mycobacterium of the present invention is administered within 1 day, 2 days, 5 days, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, or 70 days of tumor resection, which may be an R0 resection, an R1 resection, or an R2 resection, as appropriate, preferably an R0 resection, and not administered after 70 days. Alternatively, the combination or mycobacterium of the present invention described herein is administered in one or more doses within 1 day, 2 days, 5 days, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, or 70 days prior to a planned R0, R1, or R2 tumor resection, most preferably an R0 resection. In yet another embodiment, the combination or mycobacterium of the present invention described herein is administered in one or more doses within 1 day, 2 days, 5 days, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, or 70 days before a planned R0, R1, or R2 tumor resection, most preferably an R0 resection, followed by administration of the combination or mycobacterium of the present invention, with either or both administered within 1 day, 2 days, 5 days, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, or 70 days after the tumor resection.

[0123] In another embodiment, within 70 days after tumor resection, an initial dose of 1.0 mg of mycobacterium is administered intradermally, followed by an initial infusion of atezolizumab 14±2 days later, followed by intravenous atezolizumab at a dose of 840 mg every 2 weeks for 12 months after tumor resection, in addition to mycobacterium at a dose of 0.5 mg every 2 weeks for 1 month, followed by mycobacterium at a dose of 0.5 mg every 4 weeks for 11 months, which may be administered on the same or different days as the atezolizumab infusion, and preferably the mycobacterium is Mycobacterium obuense (M. obuense) NCTC13365.

[0124] In another embodiment, atezolizumab is administered intravenously at a dose of 1200 mg 28 days and 7 days before tumor resection, and mycobacterium is administered intradermally at a dose of 1.0 mg 35 days before tumor resection, followed by mycobacterium at a dose of 0.5 mg 21 days and 5 days before tumor resection, preferably where the mycobacterium is Mycobacterium obuense NCTC13365.

[0125] In another embodiment, following surgery (adjuvant therapy setting), atezolizumab is administered intravenously at a dose of 840 mg every two weeks for at least 12 months following the tumor resection, and mycobacterium is administered intradermally at a dose of 1.0 mg following the tumor resection, followed by mycobacterium at a dose of 0.5 mg every two weeks for one month, followed by mycobacterium at a dose of 0.5 mg every four weeks for 11 months, which may be administered on the same or different days as the atezolizumab infusion, and preferably the mycobacterium is Mycobacterium obuense (M. obuense NCTC13365).

[0126] In another embodiment, the invention comprises a periadjuvant regimen in which atezolizumab is administered intravenously at a dose of 1200 mg 28 days and 7 days before tumor resection, and mycobacterium is administered intradermally at a dose of 1.0 mg 35 days before tumor resection, followed by mycobacterium at a dose of 0.5 mg 21 days and 5 days before tumor resection (neoadjuvant setting), and after said surgery (adjuvant setting), atezolizumab is administered intravenously for 24 hours or more for 12 months or more after said tumor resection. The mycobacterium may be administered intravenously at a dose of 840 mg every week after the tumor resection, and the mycobacterium may be administered intradermally at a dose of 1.0 mg initially, followed by administration of 0.5 mg of the mycobacterium every two weeks for one month, followed by administration of 0.5 mg of the mycobacterium every four weeks for 11 months, either on the same day as the atezolizumab infusion or on different days; preferably, the mycobacterium is Mycobacterium obuense (M. obuense) NCTC13365.

[0127] In another embodiment, the invention comprises a neoadjuvant, adjuvant, or periadjuvant therapeutic regimen in a human subject, wherein the non-pathogenic, non-viable mycobacterium and one or more additional anti-cancer treatments or agents are administered, optionally on the same or different days, via the same or different routes of administration, and wherein the human subject exhibits a pathological complete response or partial / subtotal response or tumor regression 5 weeks or more after surgery or after the end of treatment, and / or an increase in disease-free survival (DFS) or overall survival (OS) 1, 2, 3, or 5 years or more after surgery or after the end of treatment, and / or an improvement in quality of life (EORTC). and / or show no detectable ctDNA at or after 12 months post-surgery or after the end of treatment, and preferably the mycobacterium is Mycobacterium obuense (M. obuense NCTC13365).

[0128] Circulating tumor DNA ("ctDNA") is DNA present in the bloodstream and originates from cancerous cells and tumors. Measurement of ctDNA has emerged as a promising blood-based biomarker for monitoring disease status in patients with advanced cancer. The presence of ctDNA in the blood is the result of biological processes, namely tumor cell apoptosis and / or necrosis, and can be used to monitor various cancers by targeting cancer-specific mutations.

[0129] In another embodiment of the present invention, an immunomodulatory agent for use in the adjuvant, neoadjuvant or periadjuvant treatment, reduction, inhibition or control of cancer in a patient who has undergone or will undergo tumor resection or checkpoint inhibitor therapy, optionally further comprising the administration of one or more additional anti-cancer agents or anti-cancer treatments, and who optionally does not exhibit metastasis to any organ distant from the primary tumor, comprising non-pathogenic, non-viable mycobacteria that mediate any combination of at least one of the following immunostimulatory effects on the immune system: The mycobacterium is preferably Mycobacterium obuense (M. obuense) NCTC13365, and the immunomodulatory agent is provided to: (i) increase immune response, (ii) increase T cell activation, (iii) increase cytotoxic T cell activity, (iv) increase NK cell activity, (v) increase Th17 activity, (vi) reduce T cell suppression, (vii) increase pro-inflammatory cytokine secretion, (viii) increase IL-2 secretion; (ix) increase interferon-γ production by T cells, (x) increase Th1 response, (xi) decrease Th2 response, (x (ii) reduction or elimination of at least one of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), iMCs, mesenchymal stromal cells, and TIE2-expressing monocytes; (xiii) reduction in regulatory cell activity and / or the activity of one or more of myeloid-derived suppressor cells (MDSCs), iMCs, mesenchymal stromal cells, and TIE2-expressing monocytes; (xiv) reduction or elimination of M2 macrophages; (xv) reduction in M2 macrophage pro-tumorigenic activity; (xvi) reduction or elimination of N2 neutrophils; (xvii) reduction in N2 neutrophil pro-tumorigenic activity; and (xviii) T cell activation. (xix) reducing the inhibition of CTL activation, (xx) reducing the inhibition of NK cell activation, (xxi) reversing T cell exhaustion, (xxii) increasing T cell responses, (xxiii) increasing the activity of cytotoxic cells, (xxiv) stimulating antigen-specific memory responses, (xxv) inducing apoptosis or lysis of cancer cells, (xxvi) stimulating cytotoxic or cytostatic effects on cancer cells, (xxvii) inducing direct cancer cell killing, and / or (xxviii) inducing complement-dependent cytotoxicity, and / or (xxix) inducing antibody-dependent cell-mediated cytotoxicity.

[0130] In some embodiments of the invention, an immunomodulatory agent may be administered as adjuvant therapy during and / or after tumor resection or checkpoint inhibitor therapy. This post-operative or adjuvant therapy may be used for a period appropriate for the patient. In some embodiments, an immunomodulatory agent may be further administered after tumor resection or checkpoint inhibitor therapy for a period of up to two years or more. In a preferred embodiment, an immunomodulatory agent may be further administered after surgery or checkpoint inhibitor therapy for a period of 12 months.

[0131] In some further embodiments, after tumor resection or checkpoint inhibitor therapy, the patient may further be administered one or more additional anti-cancer treatments or agents, as described above, with or without an immunomodulatory agent. In some embodiments, the one or more additional anti-cancer treatments or agents may be administered for a period of up to two years or more after tumor resection or checkpoint inhibitor therapy. In preferred embodiments, the one or more additional agents or treatments may be administered for a period of 12 months after surgery or checkpoint therapy. In some embodiments, the one or more additional anti-cancer treatments or agents may be administered in combination with an immunomodulatory agent after surgery or checkpoint therapy.

[0132] As will be appreciated by those skilled in the art, dosages and protocols for adjuvant therapy as described herein may vary depending on what is appropriate for a particular patient and / or treatment. By way of example, adjuvant therapeutic administration of the immunomodulatory agent of the present invention and / or additional anti-cancer therapy or anti-cancer agent may be administered daily, weekly, every two weeks, every three weeks, every four weeks, monthly, or every two months following surgery or treatment. In some preferred embodiments, the immunomodulatory agent and / or additional anti-cancer agent may be administered every four weeks following surgery or treatment. In the most preferred embodiment, the immunomodulatory agent and / or additional anti-cancer agent may be administered every four weeks following surgery or treatment for a total of 12 months.

[0133] In other embodiments, the immunomodulatory agent and / or additional anti-cancer treatment or agent may be administered in a periadjuvant therapeutic protocol, i.e., both before and after surgery and / or treatment. Such periadjuvant therapeutic protocols may include any combination of neoadjuvant and / or adjuvant therapies disclosed herein.

[0134] Periajuvant administration of the immunomodulatory agent and / or additional anti-cancer treatment or agent may be administered while the cancer or tumor is present in the patient or until the cancer has regressed or stabilized (e.g., SD or PR per RECIST 1.1 or similar criteria), or may even continue to be administered to the patient after the cancer or tumor has regressed or stabilized.

[0135] In another embodiment, the methods of the invention include one or more of the following: 1) reducing or inhibiting the growth, proliferation, migration, or invasion of tumor or cancer cells that have the potential to metastasize or that cause metastasis; 2) reducing or inhibiting the formation or establishment of metastases that arise from a primary tumor or cancer to one or more other sites, locations, or regions different from said primary tumor or cancer; 3) reducing or inhibiting the growth or proliferation or metastasis of metastases at one or more other sites, locations, or regions different from said primary tumor or cancer after metastases have formed or established; 4) reducing or inhibiting the formation or establishment of further metastases after metastases have formed or established; 5) increasing overall survival; 6) increasing progression-free survival; 7) disease stabilization; 8) improving quality of life.

[0136] In another embodiment, the methods of the present invention result in enhanced therapeutic efficacy as measured by a reduction or stabilization of tumor size, e.g., subtotal regression indicated by less than 10% viable tumor cells present in a resected tumor, of one or more of said tumors as defined by RECIST 1.1, optionally including stable disease (SD), complete response (CR), or partial response (PR) of a target tumor; and / or stable disease (SD) or partial response (PR) or complete response (CR) of one or more non-target tumors.

[0137] In another embodiment, the present invention provides a method for treating or controlling cancer, including a primary tumor, in a patient who has undergone or will undergo tumor resection, comprising administering to the subject simultaneously, separately, or sequentially: (i) a non-pathogenic, non-viable mycobacterium; (ii) tumor resection; and (iii) one or more additional anti-cancer treatments or anti-cancer agents, which method results in enhanced therapeutic efficacy compared to administration of the non-pathogenic, non-viable mycobacterium alone, administration of the one or more additional anti-cancer treatments or anti-cancer agents alone, or tumor resection alone.

[0138] In another embodiment, the invention provides a method that results in a subtotal regression, stable disease (SD), complete response (CR), or partial response (PR) as indicated by less than 10% viable tumor cells present in a tumor biopsy or resected tumor of the primary tumor (preferably when assessed 12 months after surgery or at the end of treatment) as assessed by Immune-Related Response Criteria (irRC), iRECIST, RECIST1.1, or irRECIST; and / or stable disease (SD) or complete response (CR) of one or more non-target tumors.

[0139] A major pathological response in more than 10%, or more than 20%, or preferably more than 30% of the tumor can be considered clinically significant, defined as a complete or subtotal regression, preferably indicated by less than 10% viable tumor cells in the tumor biopsy or resected tumor.

[0140] In another embodiment, the present invention provides methods that result in: (1) reducing or inhibiting the formation or establishment of metastases that arise from a primary tumor or cancer at one or more other sites, locations, or regions distinct from said primary tumor or cancer; (2) reducing or inhibiting the growth or proliferation or metastases at one or more other sites, locations, or regions distinct from said primary tumor or cancer after metastases have formed or established; (3) reducing or inhibiting the formation or establishment of further metastases after metastases have formed or established; (4) increasing overall survival; (5) increasing progression-free survival; (6) disease stabilization; (7) improving quality of life; and combinations thereof.

[0141] In embodiments of the present invention, the combinations and methods disclosed herein provide a detectable or measurable improvement or overall response according to an irRC (derived from timepoint response assessments and based on tumor burden), including one or more of the following: (i) irCR: complete disappearance of all lesions, measurable or not, and no new lesions (confirmed by repeated serial assessments for at least four weeks from the first recorded data); (ii) irPR: a 50% or greater reduction in tumor burden compared to baseline (confirmed by serial assessments for at least four weeks after the first recorded data). The methods of the present invention may not be immediately effective. For example, an increase in the number or mass of neoplasia, tumor, or cancer cells may occur after treatment, but over time, a stabilization or reduction in tumor cell mass, size, or cell number may eventually occur in a given subject.

[0142] In an embodiment of the invention, the combinations and methods disclosed herein result in a clinically meaningful improvement in one or more markers of disease status and disease progression selected from one or more of the following, preferably assessed 12 months after surgery or at the end of treatment: (i): overall survival; (ii): progression-free survival; (iii): overall response rate; (iv): reduction in metastatic disease; (v): blood levels of tumor antigens such as carbohydrate antigen 19.9 (CA19.9), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), or other tumor antigens depending on the tumor; (vii) nutritional status (weight, appetite, serum albumin); (viii): systemic immune-inflammatory index (SII) or systemic inflammation score (SIS); (ix): pain control or analgesic use; or (x): CRP / albumin ratio or prognostic nutrition index (PNI); or (xi) improved quality of life; or (xii) reduction or elimination of ctDNA.

[0143] In some embodiments, one or more markers of disease state and disease progression selected from the list above may be measured to monitor the treatment, reduction, inhibition, or control protocols of the present invention. In some preferred embodiments, the one or more biomarkers may include any one or more of prostate-specific antigen (PSA); carcinoembryonic antigen (CEA); prognostic nutrition index (PNI); systemic immune-inflammatory index (SII); and systemic inflammation score (SIS).

[0144] The immunomodulatory agent and / or one or more additional anti-cancer agents may be provided as separate medicaments for administration at the same time or at different times.

[0145] Preferably, the non-viable mycobacterium and / or one or more additional anti-cancer agents are provided as separate medicaments for administration at different times. When administered separately and at different times, the non-viable mycobacterium and / or one or more additional anti-cancer agents may be administered first; however, it is preferred to administer the checkpoint inhibitor and / or costimulatory checkpoint binder followed by the non-viable mycobacterium. Also, both may be administered on the same or different days, and may be administered using the same or different schedules during a treatment cycle.

[0146] In an embodiment of the invention, a treatment cycle consists of neoadjuvant, adjuvant, or periadjuvant administration of non-viable mycobacteria daily, weekly, biweekly, or monthly, optionally concomitantly with an anti-cancer drug or checkpoint inhibitor and / or costimulatory checkpoint conjugate every week, every two weeks, every three weeks, every four weeks, or more. Alternatively, the non-viable mycobacterium is administered before and / or after administration of an additional anti-cancer drug, before surgery or treatment, and optionally further after surgery or treatment.

[0147] In another embodiment of the invention, the non-viable mycobacterium is administered to the patient before and after the administration of an additional anti-cancer agent, i.e., in one embodiment, the non-pathogenic, non-viable mycobacterium is administered to the patient before and after the administration of said additional anti-cancer agent.

[0148] Alternatively, administration of one or more additional anti-cancer agents may occur simultaneously with administration of an effective amount of non-viable mycobacteria.

[0149] A subject scheduled to undergo checkpoint inhibition therapy or surgery of the present invention may do so simultaneously, separately, or sequentially with administration of non-viable mycobacteria.

[0150] In one embodiment of the invention, an effective amount of non-pathogenic, non-viable mycobacterium may be administered as a single dose. Alternatively, the effective amount of non-viable mycobacterium may be administered in multiple (repeated) doses, for example, two or more, three or more, four or more, five or more, ten or more, or twenty or more repeated doses. When multiple doses of mycobacterium are administered, there may be a period of one week, two weeks, three weeks, four weeks, or a combination of the above periods between doses.

[0151] The non-pathogenic, non-viable mycobacterium may be administered about 8 weeks, about 6 weeks, or about 4 weeks, and / or about 1 day, e.g., about 4 weeks to about 1 week, about 3 weeks to about 1 week, or about 3 weeks to 2 weeks, prior to checkpoint inhibitor therapy or surgery. Administration may be in a single dose or, more preferably, multiple doses. In a preferred embodiment, the immunomodulatory agent may be administered at least three times prior to treatment or surgery.

[0152] In one embodiment of the invention, the non-viable mycobacterium may be in the form of a pharmaceutical that is administered to a patient in a dosage form.

[0153] In certain examples, the container of the present invention may be a vial, an ampoule, a syringe, a capsule, a tablet, or a tube. In some examples, the mycobacterium may be lyophilized and formulated for resuspension prior to administration. However, in other examples, the mycobacterium is suspended in a volume of a pharmaceutically acceptable liquid. In some of the most preferred embodiments, a container is provided containing a single unit dose of mycobacterium suspended in a pharmaceutically acceptable carrier, the unit dose being about 1 x 10 3 ~Approx. 1×10 12 organisms, or approximately 1 × 10 6 ~Approx. 1×10 9 In some very specific embodiments, the liquid containing suspended mycobacteria is provided in a volume of about 0.01 ml to about 10 ml, or in a volume of about 0.03 ml to about 2 ml, or in a volume of about 0.1 ml to about 1 ml. Such compositions provide ideal units for the immunotherapeutic applications described herein.

[0154] Embodiments discussed in the context of a method and / or composition of the invention may also be used with respect to any other method or composition described herein, i.e., an embodiment with respect to one method or composition may also be applied to other methods and compositions of the invention.

[0155] The mycobacterial compositions of the present invention typically comprise an effective amount of mycobacterium dispersed in a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable or pharmacologically acceptable" refers to molecular species and compositions that do not elicit adverse, allergic or other untoward reactions when administered appropriately to an animal, e.g., a human.

[0156] In a preferred embodiment, the non-pathogenic, non-viable mycobacteria are administered via a parenteral route selected from subcutaneous, intradermal, subdermal, intraperitoneal, intravenous, and intravesical injections, or intratumoral, peritumoral, perilesional, or intralesional administration. Intradermal injection allows delivery of the full proportion of the mycobacterial composition to the dermal layer, which is accessible to immune surveillance mechanisms, and can therefore elicit anti-cancer immune responses and promote immune cell proliferation in local lymph nodes.

[0157] In another embodiment, the immunomodulatory agent is administered into the patient's skin via a microneedle device comprising multiple microneedles, as disclosed in WO 2021 / 136933, which is incorporated herein by reference.

[0158] Other preferred microneedle devices for use in accordance with the present invention include the North Carolina State University (described in WO 2017 / 151727), Debioject microneedles (Debiotech, Switzerland), Micronject 600 (NaoPass, Israel, described in WO 2008 / 047359), Nanopatch (Vaxxas, USA), SOFUSA (Kimberly-Clark, USA, described in WO 2017 / 189259 and WO 2017 / 189258), dissolution microarrays from Micron Biomedical, and MIMIX dissolution controlled release microarrays (Vaxxas, USA).

[0159] All publications mentioned in the above specification are incorporated herein by reference. Various modifications and variations of the described methods and systems of the present invention will be apparent to those skilled in the art without departing from the spirit and scope of the invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in biochemistry and immunology or related fields are intended to be within the scope of the following claims.

[0160] The invention will now be further described with reference to the following non-limiting examples.

[0161] Example 1 A study was developed to investigate the adjuvant therapeutic effect of atezolizumab in combination with a heat-killed whole-cell preparation of Mycobacterium obuense (IMM-101) in patients with stage III colorectal cancer with high MSI who are ineligible for oxaliplatin-based chemotherapy, along with a safety and efficacy study of such treatment.

[0162] Patients to be treated had histologically confirmed adenocarcinoma of the colon or rectum with pathological stage III disease and were ineligible for or refused adjuvant oxaliplatin-based chemotherapy.

[0163] This study aims to determine whether the adjuvant combination of IMM-101 and atezolizumab is well tolerated, to investigate the efficacy signal of the combination, and to measure 12-month cell-free DNA (cfDNA-free) survival rates.

[0164] A total of 100 patients will be enrolled, 50 in Cohort A and 50 in Cohort B. A sample size of N=50 is believed to provide a reasonably reliable estimate of the 12-month cfDNA-free rate of the experimental combination therapy and allows for measurement of actual confirmed survival rates for a prospectively enrolled cohort of dMMR patients in the ColoPredict registry.

[0165] Cohort A will receive atezolizumab at a dose of 1200 mg administered intravenously every three weeks for 12 months. Cohort B will receive atezolizumab at a dose of 1200 mg administered intravenously every three weeks for 12 months in combination with IMM-101 administered every two weeks for three doses, then every four weeks for a total of 12 months.

[0166] IMM-101 will be administered as a single intradermal injection of 0.1 mL of IMM-101 (10 mg / mL; a sterile suspension of heat-killed Mycobacterium obuense NCTC13365 in borate-buffered saline) into the skin overlying the deltoid muscle, alternating arms for each administration. Investigators will be appropriately trained in intradermal injection techniques.

[0167] Prior clinical studies with IMM-101 suggested that this dose was safe and well tolerated. Skin reactions occurring at the injection site were characterized by erythema, local swelling, and occasionally mild ulceration. All symptoms were expected given the product's known pharmacology and previous clinical studies. Furthermore, data from safety and tolerability studies with IMM-101 demonstrated that skin reactions resolved sufficiently over time and did not impair daily activities.

[0168] Under physician supervision, with resuscitation equipment available as a precaution, vital signs will be monitored for at least two hours following the first dose of IMM-101 administered to each patient in the study.

[0169] The treatment regimen involves IMM-101 administered once every two weeks for the first three doses, followed by a four-week rest period, followed by once every two weeks for the next three doses. This is followed by once every four weeks, allowing for a ±2-day time window. The loading dose of IMM-101 before surgery is intended to be 1.0 mg followed by 0.5 mg, and / or the loading dose of IMM-101 after surgery is intended to be 1.0 mg followed by 0.5 mg.

[0170] Atezolizumab will be administered intravenously at a dose of 1200 mg every 3 weeks for 12 months.

[0171] Treatment for patients in both cohorts will continue for 12 months or until disease progression (assessed by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1), subject to the earlier of: unacceptable side effects, investigator decision to discontinue treatment, patient withdrawal of consent, or 18 months of IMM-101 treatment. Patients whose complete response is maintained across two scans should continue treatment unless the investigator deems this not to be in the patient's best interest. Patients in Cohort A and Cohort B who have documented disease progression may continue on study treatment if they have clinical benefit, do not have a decline in performance status, are free of clinically relevant adverse effects from study treatment as determined by the investigator, or are not deemed to require alternative treatment.

[0172] Example 2 A preliminary substudy to Example 1 was developed to evaluate the efficacy of neoadjuvant atezolizumab with or without IMM-101 in patients with MSI-rich, clinical stage III colorectal cancer based on preoperative CT scans for pathological complete regression (pCR) or near-complete (subtotal) regression (<10% viable tumor cells) after 6 weeks of treatment, as well as to assess the safety and tolerability of such a treatment protocol.

[0173] Twenty of the 100 patients from Example 1 with clinical stage III disease based on preoperative CT scans will be randomized 1:1 to receive neoadjuvant atezolizumab and / or IMM-101 for 6 weeks. After resection, these patients will receive the adjuvant therapy of Example 1 for an additional 12 months.

[0174] Cohort A (10 patients) will receive 1200 mg of atezolizumab intravenously every 3 weeks for 6 weeks preoperatively and for 12 months post-excision. Cohort B (10 patients) will receive 0.1 ml of a 10 mg / ml IMM-101 solution intradermally every 2 weeks for 3 doses preoperatively and then every 4 weeks for a total of 12 months in the adjuvant setting described in Example 1.

[0175] Example 3 A study was developed to investigate the adjuvant therapeutic effect of atezolizumab in combination with a heat-killed whole-cell preparation of Mycobacterium obuense (IMM-101) in patients with MSI-H / dMMR stage III colorectal cancer in whom oxaliplatin regimens are not a viable treatment option.

[0176] Eligible patients were those with histologically confirmed adenocarcinoma of the colon or rectum with high MSI and dMMR pathological stage III disease, ECOG status 0-2, who had undergone R0 tumor resection, and who were ineligible for or refused oxaliplatin-based adjuvant chemotherapy.

[0177] The study aims to determine whether the adjuvant combination of IMM-101 and atezolizumab is well tolerated and to investigate the efficacy signal of the combination, as well as to determine whether the adjuvant combination of IMM-101 and atezolizumab can significantly improve 3-year disease-free survival, and to assess the ctDNA-free rate, defined as the proportion of patients with no detectable ctDNA 12 months after adjuvant treatment.

[0178] A total of 100 patients will be enrolled, 50 in Cohort A and 50 in Cohort B. A sample size of N=50 is believed to provide a reasonably reliable estimate of 3-year disease-free survival for the experimental combination therapy and allows for measurement of actual confirmed survival rates for a prospectively enrolled cohort of patients with stage III dMMR tumors in the ColoPredict registry.

[0179] Cohort A will receive a single 840 mg dose of atezolizumab administered intravenously every 2 weeks for 12 months in the adjuvant setting.

[0180] Cohort B will receive a single loading dose of 1.0 mg of IMM-101 intradermally in the adjuvant setting, 14 ± 2 days before the start of atezolizumab treatment. Patients will then receive 840 mg of atezolizumab intravenously every 2 weeks for 12 months, in combination with 0.5 mg of IMM-101 intradermally every 2 weeks for 1 month, followed by 0.5 mg of IMM-101 intradermally every 4 weeks for a total of 12 months.

[0181] The initial dose of IMM-101 will be 0.1 mL (1.0 mg), followed by 0.05 mL (0.5 mg) of IMM-101 administered intradermally into the skin over the deltoid muscle, alternating arms for each dose. Investigators will be appropriately trained in intradermal injection techniques.

[0182] Preliminary clinical studies with IMM-101 suggested that this dose was safe and well-tolerated. Skin reactions at the injection site were characterized by erythema, local swelling, and occasionally mild ulceration. All symptoms were expected given the product's known pharmacology and previous clinical studies. Furthermore, data from safety and tolerability studies with IMM-101 demonstrated that skin reactions resolved sufficiently over time and did not impair daily activities. Under physician supervision, with resuscitation equipment available as a precaution, vital signs were monitored for at least two hours after the first dose of IMM-101 administered to each patient in the study. Patients were followed for three years after the last dose of treatment. The primary endpoint was assessment of DFS rate at the three-year milestone. Secondary endpoints included DFS / OS at one, two, and five years, safety, quality of life, and the proportion of ctDNA-free patients 12 months after the end of treatment (see Figure 1).

[0183] Patient inclusion criteria included hemoglobin of at least 9 g / dL; AST(SGOT) / ALT(SGPT) values ​​of 2.5 or less; and endpoints further included death from any cause 3 years after randomization.

[0184] Example 4 A pilot substudy to Example 3 was developed to evaluate the efficacy of perioperative / periadjuvant atezolizumab plus IMM-101 in patients with MSI-rich / dMMR clinical stage III colorectal cancer for whom oxaliplatin regimens are not a viable treatment option (or have been rejected) for pathological complete regression (pCR) or near-complete (subtotal) regression (<10% viable tumor cells) after 5 weeks of treatment, as well as for disease-free survival and overall survival.

[0185] A total of 20 patients will be enrolled. Patients to be treated will have histologically confirmed MSI-high / dMMR clinical stage III adenocarcinoma of the colon or rectum who are ineligible for or have refused oxaliplatin-based adjuvant chemotherapy, ECOG status 0-2, and resectable primary tumors. Following resection, these patients will receive an additional 12 months of adjuvant therapy according to Example 3, Cohort B.

[0186] Specifically, enrolled patients will receive a single 1200 mg dose of intravenous atezolizumab 28 and 7 days before tumor resection, in combination with a single 1.0 mg dose of IMM-101 administered intradermally 35 days before tumor resection, followed by a single 0.5 mg dose of IMM-101 administered 21 and 5 days before tumor resection.

[0187] Within 70 days after resection, 14±2 days prior to the initiation of atezolizumab treatment, patients will receive a single loading dose of 1.0 mg of IMM-101 administered intradermally. This will be followed by an 840 mg intravenous atezolizumab dose every 2 weeks for 12 months, in combination with a 0.5 mg dose of IMM-101 administered every 2 weeks for 1 month, followed by every 4 weeks for a total of 12 months, in the adjuvant setting of Example 3, Cohort B. Patients will be followed for 3 years after the last dose of treatment. The primary endpoint is assessment of DFS rate at the 3-year milestone, and secondary endpoints include DFS / OS at 1, 2, and 5 years, safety, QoL, and the proportion of ctDNA-free patients 12 months after the end of treatment (see Figure 2).

Claims

1. 1. An immunomodulatory agent for use in the adjuvant, neoadjuvant or periadjuvant therapy, treatment, reduction, inhibition or control of cancer, including primary tumors, in patients who have undergone or will undergo tumor resection and / or administration of one or more additional anti-cancer treatments or agents, comprising: including non-pathogenic non-viable mycobacteria, Immunomodulators.

2. 2. The immunomodulatory agent for use according to claim 1, wherein the patient does not present metastasis in any organ distant from the primary tumor and does not present macroscopic residual disease after tumor resection as indicated by an R2 resection status.

3. The one or more additional anti-cancer treatments or agents may be selected from the group consisting of adoptive cell therapy, surgical therapy, chemotherapy, radiation therapy, hormone therapy, checkpoint inhibitor therapy, small molecule therapy such as metformin, receptor kinase inhibitor therapy such as tyrosine kinase inhibitor therapy, hyperthermia, phototherapy, radiofrequency ablation therapy (RFA), anti-angiogenic therapy, cytokine therapy, cryotherapy, biological therapy, HDAC inhibitors, e.g., OKI-179, BRAF inhibitors, MEK inhibitors, EGFR inhibitors, VEGF inhibitors, P13Kδ inhibitors, PARP inhibitors, mTOR inhibitors, hypomethylating agents, oncolytic viruses, TLR2 agonists, TLR3 agonists, such as rintatolimod.

3. The immunomodulatory agent for use according to claim 1 or claim 2, wherein the immunomodulatory agent is selected from TLR agonists including anti-cancer drugs, TLR4 agonists, TLR7 agonists, TLR8 agonists or TLR9 agonists, or TLR5 agonists such as MRx0518 (4D Pharma), STING agonists (including MIW815 and SYNB1891), mifamurtide, and cancer vaccines such as GVAX or CIMAVAX, and combinations thereof, preferably wherein the patient has undergone or will undergo tumor resection and / or checkpoint inhibitor therapy.

4. 4. The immunomodulator for use according to any one of claims 1 to 3, wherein the cancer is selected from bladder cancer (including non-muscle invasive bladder cancer), prostate cancer, liver cancer, renal cancer, lung cancer, breast cancer, colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, brain cancer (including glioblastoma), hepatocellular carcinoma, lymphoma, leukemia, gastric cancer, cervical cancer, ovarian cancer, thyroid cancer, melanoma, head and neck cancer, skin cancer, and soft tissue sarcoma and / or osteosarcoma (including pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (PNET)).

5. 5. The immunomodulator for use according to claim 4, wherein the cancer is metastatic.

6. 6. The immunomodulator for use according to any one of claims 1 to 5, wherein the cancer is clinically defined according to the TNM classification criteria, in which the patient has a primary tumor (T) of T1 to T4 and / or a nodal metastasis (Node designation) of N0, N1 or N2, or the cancer is clinically defined as being at stage I, II or III.

7. 7. The immunomodulatory agent for use according to claim 6, wherein the patient has no evidence of metastasis (M0) as defined by the TNM classification criteria.

8. The immunomodulator for use according to any one of claims 1 to 7, wherein the patient has undergone or is about to undergo a tumor resection, the tumor resection further comprising lymph node dissection.

9. 9. The immunomodulator for use according to any one of claims 1 to 8, wherein the patient has undergone or will undergo a tumor resection, which further comprises a metastatic tumor resection in the presence of metastatic disease such as metastatic pancreatic ductal adenocarcinoma (mPDAC).

10. The immunomodulator for use according to any one of claims 1 to 9, wherein the cancer is determined to be microsatellite instability (MSI) high or MSI low as measured by a PCR based assay and / or the cancer undergoes IHC staining for DNA mismatch repair deficient (dMMR) or proficient (pMMR) protein expression, preferably the cancer is MSI high and dMMR.

11. 11. The immunomodulator for use according to any one of claims 1 to 10, wherein the cancer is stage III colorectal cancer of the MSI-high or MMR-deficient type, preferably wherein the patient is ineligible for oxaliplatin-based chemotherapy, or wherein the cancer is selected from locally advanced pancreatic cancer (with or without nodal disease), resectable pancreatic cancer, borderline resectable pancreatic cancer, unresectable pancreatic cancer, checkpoint resistant pancreatic cancer, chemotherapy resistant pancreatic cancer, oligometastatic pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), and metastatic pancreatic ductal adenocarcinoma (mPDAC).

12. Non-pathogenic, non-viable mycobacteria include strains deposited under accession numbers NCTC 11659 and related designations such as SRL172, SRP299, IMM-201, DAR-901, and the strain deposited as ATCC 95051 (Vaccae™); Mycobacterium vaccae (M. vaccae); Mycobacterium obuense (M. obuense); M. paragordonae (strain 49061), M. parafortuitum, M. paratuberculosis, M. brumae, M. aurum, M. indicus Mycobacterium indicus pranii, Mycobacterium w (M.w), Mycobacterium manresensis, Mycobacterium kyogaense (M.kyogaense) (deposited as DSM107316 / CECT9546), Mycobacterium phlei (M.phlei), Mycobacterium smegmatis, Mycobacterium tuberculosis Aoyama B (M.tuberculosis Aoyama B), B) or H37Rv, RUTI, BCG, VPM1002BC, SMP-105, Z-100, and combinations thereof, preferably a strain of Mycobacterium obuense deposited under the Budapest Treaty under accession number NCTC 13365.

13. 13. The immunomodulator for use according to claim 12, wherein the non-pathogenic, non-viable mycobacterium is Mycobacterium obuense NCTC13365, preferably in rough form and / or presented as a fraction, fragment, subcellular component, lysate, homogenate, sonicate or in the form of substantially whole cells.

14. The immunomodulatory agent is 3 ~10 9 The immunomodulator for use according to any one of claims 1 to 13, administered in a dose comprising cells or between 0.0001 and 1.0 mg, preferably between 0.5 mg and 1.0 mg.

15. 15. The immunomodulatory agent for use according to any one of claims 1 to 14, administered at least 1 to 3 times prior to tumor resection and / or administration of said one or more additional anti-cancer treatments or agents, preferably checkpoint inhibitor therapy.

16. 16. The immunomodulatory agent for use according to claim 15, administered three times prior to tumor resection and / or administration of said one or more additional anti-cancer treatments or agents (preferably checkpoint inhibitor therapy).

17. 17. The immunomodulatory agent for use according to any one of claims 1 to 16, administered following tumour resection or said one or more additional anti-cancer treatments or agents (preferably checkpoint inhibitor therapy), optionally for a period of 12 months or more.

18. 18. The immunomodulatory agent for use according to any one of claims 1 to 17, wherein both the immunomodulatory agent and said one or more additional anti-cancer treatments or anti-cancer agents (preferably checkpoint inhibitor therapy) are administered before and / or after tumour resection, optionally for a period of 12 months or more following said tumour resection.

19. The immunomodulator for use according to any one of claims 1 to 18, which is administered via parenteral, oral, sublingual, nasal or pulmonary route.

20. 20. The immunomodulator for use according to claim 19, wherein the parenteral route is selected from subcutaneous, intradermal, intranodal, intramuscular, subdermal, intraperitoneal, or intravenous administration, and the parenteral route optionally comprises intratumoral, peritumoral, perilesional, or intralesional administration.

21. 21. The immunomodulator for use according to claim 20, wherein intratumoral or intralesional administration is followed by intradermal injection.

22. The one or more anticancer drugs may be selected from the group consisting of bevacizumab, cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, mustine, vincristine, procarbazine, prednisolone, bleomycin, vinblastine, dacarbazine, etoposide, cisplatin, epirubicin, capecitabine, leucovorin, folinic acid, carboplatin, oxaliplatin, gemcitabine, paclitaxel, nalifoxin, nalofoxin, moxibustion, and rituximab.

22. The immunomodulatory agent for use according to any one of claims 1 to 21, wherein the one or more additional anti-cancer therapies or anti-cancer agents are selected from rinotecan, nab-paclitaxel, pemetrexed, irinotecan, temozolomide, and combinations thereof, and wherein the one or more additional anti-cancer therapies or anti-cancer agents are administered intratumorally, intra-arterially, intravenously, intravascularly, intrapleurally, intraperitoneally, intratracheally, intranasally, transpulmonary, intrathecally, intramuscularly, endoscopically, intralesional, percutaneously, subcutaneously, topically, stereotactically, orally, or by direct injection or perfusion.

23. The administration / administration of said one or more additional anti-cancer therapies or agents is preferably selected from the group consisting of ipilimumab, nivolumab, pembrolizumab, atezolizumab, BI754091 (anti-PD-1 agent), bavituximab (anti-PS IgG3 monoclonal antibody), vintrafusp alfa, durvalumab, dostallimab, tremelimumab, spartalizumab, avelumab, sintilimab, toripalimab, prolgolimab, tislelizumab, camrelizumab, MGA012, MGD013 (now known as tebotelimab), MGD014 (now known as tebotelimab), MGD015 (now known as tebotelimab), MGD016 (now known as tebotelimab), MGD017 (now known as tebotelimab), MGD018 (now known as tebotelimab), MGD019 (now known as tebotelimab), MGD020 (now known as tebotelimab), MGD021 (now known as tebotelimab), MGD022 (now known as tebotelimab), MGD023 (now known as tebotelimab), MGD024 (now known as tebotelimab), MGD025 (now known as tebotelimab), MGD026 (now known as tebotelimab), MGD027 (now known as tebotelimab), MGD028 (now known as tebotelimab), MGD029 (now known as tebotelimab), MGD030 (now known as tebotelimab), MGD031 (now known as tebotelimab), MGD032 (now known as tebotelimab), MGD 019, enoblitzumab, MGD009, MGC018, MEDI0680, miptenalimab (BI754111, anti-LAG-3 agent), nimotuzumab, PDR001, FAZ053, TSR022, MBG453, leratolimab (BMS986016), LAG525 (IMP701), IMP321 (eftilagimod alfa), REG N2810 (cemiplimab), REGN3767, pexidartinib (PLX3397), LY3022855, FPA008, BLZ945, GDC0919, epacadostat, emactuzumab (RG1755 targeting CSF-1R), FPA150, indoximid, BMS986205, CPI-444, MEDI9447, PBF5 23. The immunomodulatory agent for use according to any one of claims 1 to 22, which is a checkpoint inhibitor therapy selected from: 09, FS118 (bispecific for LAG-3 and PD-L1), lirilumab, Sym023, TSR-022, A2Ar inhibitors (e.g. EOS100850, AB928), NKG2A inhibitors such as monalizumab, and combinations thereof.

24. 24. The immunomodulatory agent for use according to claim 23, wherein the one or more checkpoint inhibitors are each administered in a sub-therapeutic amount and / or for a sub-therapeutic period.

25. 25. The immunomodulatory agent for use according to any one of claims 23 or 24, wherein said one or more additional anti-cancer treatments or agents are selected from gemcitabine, nab-paclitaxel, anti-PD-1 antibodies, anti-CTLA-4 antibodies, anti-PD-L1 antibodies, and / or mTOR inhibitors, preferably atezolizumab, administered at a dosage of 1200 mg every 3 weeks or 840 mg every 2 weeks for a total of up to 12 cycles or up to 24 times.

26. 26. The immunomodulatory agent for use according to any one of claims 23 to 25, which is administered first prior to, and optionally in combination with, or subsequent to, said one or more anti-cancer treatments or agents.

27. 27. The immunomodulator for use according to claim 26, wherein said one or more anti-cancer treatments or agents is a checkpoint inhibitor therapy, preferably administered three or more times.

28. 28. The immunomodulatory agent for use according to any one of claims 1 to 27, intended to be administered following tumor resection or administration / adiminstration of said one or more additional anti-cancer treatments or agents, preferably checkpoint inhibitor therapy, optionally for a period of 3 months or more, or 6 months, or 12 months.

29. 29. The immunomodulator for use according to any one of claims 1 to 28, wherein both the immunomodulator and the one or more additional anti-cancer treatments or anti-cancer agents, preferably checkpoint inhibitor therapy, are administered before and / or after tumour resection, optionally for a period of 3 months, or 6 months, or 12 months or more after tumour resection.

30. The immunomodulator for use according to any one of claims 1 to 29, wherein said treating, reducing, inhibiting or controlling is monitored based on the measurement of one or more biomarkers.

31. 31. The immunomodulatory agent of claim 30, wherein the one or more biomarkers include any one or more of the following: prostate specific antigen (PSA); carcinoembryonic antigen (CEA); CA19.9, PNR, INR, prognostic nutrition index (PNI); systemic immune inflammation index (SII); and systemic inflammation score (SIS).

32. 32. The immunomodulatory agent for use according to any one of claims 1 to 31, wherein said treating, reducing, inhibiting or controlling said cancer, including primary tumours, results in a clinically meaningful improvement in one or more markers of disease state and disease progression selected from one or more of the following when assessed (preferably 12 months after surgery or at the end of treatment): (i) overall survival; (ii) progression free survival; (iii) disease free survival; (iv) overall response rate; (v) reduction in primary tumour size and / or metastatic disease; (vi) blood levels of tumour antigens such as carbohydrate antigen 19.9 (CA19.9) and carcinoembryonic antigen (CEA) or other tumour antigens depending on the tumour; (vii) nutritional status (body weight, appetite, serum albumin); (viii) pain control or analgesic use; (ix) CRP / albumin ratio; (x) improved quality of life; (xi) maintenance of lean body mass; and (xii) reduction or loss of ctDNA.

33. 33. The immunomodulatory agent for use according to any one of claims 1 to 32, wherein the adjuvant, neoadjuvant or periadjuvant therapy, treatment, reduction, inhibition or control of cancer, including a primary tumor, results in a subtotal regression, stable disease (SD), complete response (CR) or partial response (PR) as indicated by less than 10% viable tumor cells present in a tumor biopsy or resected tumor of the primary tumor (preferably when assessed 12 months after surgery or at end of treatment) as assessed by Immune Related Response Criteria (irRC), iRECIST, RECIST 1.1 or irRECIST; and / or a stable disease (SD) or complete response (CR) of one or more non-target tumors.

34. 34. The immunomodulatory agent for use according to any one of claims 1 to 33, wherein the adjuvant, neoadjuvant, or periadjuvant therapy, treating, reducing, inhibiting, or controlling a cancer comprising a primary tumor results in: (1) a reduction or inhibition of the formation or establishment of metastases arising from a primary tumor or cancer to one or more other sites, locations, or regions distinct from the primary tumor or cancer; (2) a reduction or inhibition of growth or proliferation or metastases at one or more other sites, locations, or regions distinct from the primary tumor or cancer after metastases have formed or established; or (3) a reduction or inhibition of the formation or establishment of further metastases after metastases have formed or established.